



(19)

---

Europäisches Patentamt

European Patent Office

## Office européen des brevets



(11)

EP 1 136 552 A1

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
26.09.2001 Bulletin 2001/39

(51) Int Cl.7: **C12N 15/12, C12N 15/11,**  
C12N 9/00, C12N 5/10,  
C07K 14/705, C07K 16/28  
C12Q 1/68, G01N 33/53,  
A61K 48/00

(21) Application number: 00105820.5

(22) Date of filing: **20.03.2000**

**(84) Designated Contracting States:**

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE

#### Designated Extension States:

Designated Extension

(71) Applicant: **Bayer Aktiengesellschaft**  
**51368 Leverkusen (DE)**

(72) Inventors:

- **Schmitz, Gerd, Prof.Dr.**  
**93161 Sinzig (DE)**
- **Bodzioch, Marek, Dr.**  
**30-601 Krakow (PL)**

(54) **ATP binding cassette transporter 1 (ABC1) gene polymorphisms and uses thereof for the diagnosis and treatment of lipid disorders, cardiovascular diseases and inflammatory diseases**

(57) The present invention provides four common polymorphisms in the gene encoding the ATP-binding cassette transporter-1 (*ABC1*), which are associated with decreased ApoA-I mediated efflux of cholesterol, the first step of reverse cholesterol transport. The provided data can be taken as evidence that common polymorphisms in *ABC1* directly affect cellular lipid homeostasis, which is a key factor in the atherogenetic proc-

ess. The frequencies of three of the common *ABC1* variants are significantly increased in a population of men having low HDL-C levels and established CHD relative to CHD-free control subjects. The use of the provided *ABC1* polymorphisms for the diagnosis and treatment of lipid disorders, cardiovascular diseases, and inflammatory diseases like psoriasis and lupus erythematoses is claimed.

Figure 2: human ABC1 gene – protein translation

EP 1 136 552 A1

EP 1 136 552 A1

ttggaaaccttacaaaatccatgtgcgtcgatgtttccatgtggcccg  
601 G N F N K S I V A R L S D A R - 650  
aggtttttttttatccatgcgcggaaatccggccatgttcggatggatccgtccaa  
651 R I L D L Y S O K D T S K I H R K - 700  
agttctgtggacatccatgcgcggaaatccggccatgttcggatggatccgtccaa  
701 V L F T L Q G I K K S S S N L K E - 750  
ttcaaggatttcttcggatggatccgtggaaatccatgttcggatggatccgtccaa  
751 Q D F L V D N B T P F S G V Y H - 800  
aaaccttccatcccaaaatgtacttgcggacatgttcggatggatccgtccaa  
801 N L S L P K S T V D K L R A D V - 850  
  
cattctccacaaggatttttccaggcttccatgttcggatggatccgtccaa  
851 I B H K V F L Q D S T L - 900  
ttccatccatccacaaggatgttcggatggatccgtccaa  
901 C N G S K S E E V I Q L G D G E - 950  
gtttctgcgttccatccacaaggatgttcggatggatccgtccaa  
951 V S E L I C S L P R E E K L A A A R E - 1000  
agttctgttcgcacatgcggatccatgttcggatggatccgtccaa  
1001 V L R S K N M D I V P T C P I L R T L N - 1050  
atcttacatccatccatccatgcggatccatgttcggatggatccaa  
1051 S T S P F F S K B L A E A T K T - 1100  
tttgtcgtatgtttttggatccatgttcggatggatccgtccaa  
1101 I L H S L S T L A Q E F S M R S - 1150  
cttggatgttcggatccatgcggatccatgttcggatggatccgtccaa  
1151 W S D M F Q E V M F L T N V N S - 1200  
ccatgcgtccatccaccaaaatccatccatgcggatccatgttcggatggatccaa  
1201 S B S T Q I Y Q A V S R I V C G - 1250  
catccggatccatccatgcggatccatgttcggatggatccgtccaa  
1251 H P E G G C C L F D N N W K B D - 1300  
ccatcaatcaatccatgcggatccatgttcggatggatccgtccaa  
1301 N Y K A L F G G N G T E E D A E - 1350  
aaatcttcgtatgcgtatccatgcggatccatgttcggatggatccaa  
1351 T P Y D N S T T P Y C N D L E K - 1400  
  
aattttggatccatgttcgttccatccatgttcggatggatccgtccaa  
1401 N L E S S P D S R I I W K A L K P - 1450  
gtctgttcgttccatgcggatccatgttcggatggatccgtccaa  
1451 I L W G K I T Y P D T P A T R Q - 1500  
aggatctgttcgtatgcggatccatgttcggatggatccgtccaa  
1501 V K A E V N K T F Q E L A V F H - 1550  
gatctgttcgtatgcggatccatgttcggatggatccgtccaa  
1551 D L E G H W E B D S P K I N T F M - 1600  
ggaaatccatgcggatccatgttcggatggatccgtccaa  
1601 E N S Q O E M D L V E M L L D S R I - 1650  
acaatgtccatgttcggatccatgttcggatggatccgtccaa  
1651 N D E F W E Q C L D G L D W T A - 1700  
ccatgcgtatgcggatccatgttcggatggatccgtccaa  
1701 Q D I V A F L A K H P E D V Q S S - 1750  
taatggatccatgttcggatggatccatgttcggatggatccgtccaa  
1751 N G S V Y T W F E A F N E T N Q A - 1800  
caatccggccatatcttcgttcgtatgcggatccatgttcggatggatccaa  
1801 I R T I S R F M E C V N L N K L - 1850  
gatccatgttcggatggatccatgttcggatggatccgtccaa  
1851 E F I K A T E V W L I N K S M E L L - 1900  
ggatgtggatccatgttcggatggatccatgttcggatggatccgtccaa  
1901 D B R K F W A G I V F T G I T P G - 1950  
gcatgttcggatggatccatgttcggatggatccatgttcggatggatccaa  
1951 S I B L P H H V K Y K I R M L I - 2000  
gataatgtggatccatgttcggatggatccatgttcggatggatccgtccaa  
2001 D N V E R T N K I K D G Y W D P G - 2050  
tcctcgatgttcggatggatccatgttcggatggatccatgttcggatggatccgtccaa  
2051 P R D A F F E D M R Y V W S G F A - 2100  
atctatgttcggatggatccatgttcggatggatccatgttcggatggatccaa  
2101 Y L Q C E V V B Q A I I R V L T G - 2150  
accgtggatccatgttcggatggatccatgttcggatggatccatgttcggatggatccaa  
2151 T E K X T G V Y H Q Q M P Y P C Y - 2200  
cggtatgttcggatggatccatgttcggatggatccatgttcggatggatccaa  
2201 T E K X T G V Y H Q Q M P Y P C Y - 2250

EP 1 136 552 A1

EP 1 136 552 A1

EP 1 136 552 A1

7251 -----+ 7260

**Description****Background of the invention**

5 [0001] Epidemiological studies have established that plasma high density lipoprotein cholesterol (HDL-C) concentrations are inversely associated with the incidence of coronary heart disease (CHD) (1-4). Moreover, HDL deficiency is the most common lipid abnormality observed in patients with premature CHD (5,6), with nearly half of all CHD patients having low concentrations of HDL-C. Genetic factors account for approximately 50% of the variation in HDL-C levels in the general population (7), with several common mutations identified in genes encoding for proteins involved in the 10 regulation of plasma HDL-C concentrations and, ultimately, playing a role in the development of CHD (8).

10 [0002] Recently, we (9,10) and others (11-15) demonstrated that familial HDL deficiency (FDH) syndromes with either splenomegalie or atherosclerosis (e.g. Tangier disease (TD); familial hypoalphaglycoproteinaemia) are rare HDL-deficiencies caused by mutations in the gene encoding the ATP-binding cassette transporter-1 (ABC1). ABC1 is a member 15 of the ATP binding cassette family of proteins that are involved in the transmembrane transport of a variety of different molecules, including bile acids, steroid hormones, ions, amino acids, sugars and vitamins (16-19). TD is characterized by severely diminished plasma HDL-C concentrations, reduced levels of low density lipoprotein cholesterol (LDL-C), the deposition of cholesteryl esters in the reticulo-endothelial system with splenomegaly and enlargement of tonsils and lymph nodes (20), as well as a predisposition to neuropathy and CHD (21,22). The HDL deficiency in these patients has been related to a rapid catabolism of HDL and a decrease in ApoA-I induced lipid efflux from various cells including 20 mononuclear phagocytes (23-25). Familial hypoalphaglycoproteinaemia represents the other clinical phenotype that is characterized by a similar disturbance in ApoA-I metabolism but is associated with an enhanced risk of CHD rather than splenomegalie. ApoA-I mediated cellular cholesterol efflux is the first step in the reverse cholesterol transport and prevents excessive cholesterol accumulation in peripheral cells. In addition, this process is suggested to contribute to the formation of mature HDL particles, thereby influencing the pool size of HDL in the plasma.

25 [0003] Although mutations in *ABC1* cause TD, the precise molecular mechanism by which they do so remains unknown. Also, little is known about the association of ABC1 and HDL metabolism in individuals not affected with TD. Previous investigations on the function of ABC1 in mice have revealed its role in the engulfment of apoptotic cells by macrophages (26) and in macrophage interleukin-1 $\beta$  secretion (27). We have further shown that ABC1 is a cholesterol-responsive modulator of cellular lipid efflux (10) and, thus, plays a significant role in cholesterol homeostasis. Moreover, the ABC1-knockout mice (*ABC1* $^{-/-}$ ) show massively reduced levels of serum lipids and lipoproteins. The expression of ABC1 in mucosa cells of the small intestine and the altered lipoprotein metabolism in *ABC1* $^{-/-}$  mice allows the 30 conclusion that ABC1 plays also a major role in intestinal resorption and translocation of lipids into the lymph-system.

**Summary of the invention**

35 [0004] Four different polymorphisms in *ABC1* (G596A, T1136C, A2589G, and G3456C) were identified in different Tangier kindreds as well as 516 healthy control subjects. Each of these polymorphisms affect the primary structure of the gene product.

40 [0005] A frequent coincidence of the G596A and A2589G polymorphisms was identified indicating that those two mutations are in linkage disequilibrium.

45 [0006] The two most common polymorphisms (G596A and A2589G) are both associated with a decreased in vitro ApoA-I mediated efflux of cholesterol from mononuclear phagocytes emphasizing the role of ABC1 in lipid efflux, the first step in reverse cholesterol transport. These results also are evidence that common polymorphisms in *ABC1* directly affect cellular lipid homeostasis, which is a key factor in the atherogenic process. A reduction of ApoA-I mediated efflux of cholesterol from mononuclear phagocytes is also a typical feature of Tangier disease.

50 [0007] Plasma lipoproteins, and HDL-cholesterol in particular, are not affected, probably because the effect of the *ABC1* polymorphisms on the protein function is compensated by other factors controlling plasma HDL levels.

[0008] Three common variants in the gene encoding ABC1 (G596A, A2589G, and G3456C) occur with significantly increased frequency in a population of men having low HDL-C as their primary lipid abnormality and established CHD, providing evidence for a role of *ABC1* in the premature CHD associated with common HDL deficiency states.

[0009] In summary, the identified polymorphisms in the *ABC1* gene can be used for diagnosis and therapy of lipid disorders, cardiovascular diseases, and inflammatory diseases.

Abbreviations

[0010]

5	ABC	ATP-binding cassette
	ANC	Anchor
10	ApoA	Apolipoprotein A
	ApoB	Apolipoprotein B
	ApoE	Apolipoprotein E
15	ATP	Adenosine triphosphate
	BMI	Body mass index
	bp	Base pairs
20	cAMP	Cyclic adenosine monophosphate
	cDNA	Copy DNA
	CH	Cholesterol
25	CHD	Coronary heart disease
	DET	Detection
30	DPM	Disintegrations per minute
	E-LDL	Enzymatically modified LDL
	f	Forward
	Fluo	Fluorescein
35	FOS	Framingham Offspring Study
	HDL	High density lipoprotein
	HDL-C	HDL-cholesterol
	kDa	Kilo Dalton
40	LDL	Low density lipoprotein
	LDL-C	LDL-cholesterol
	M-CSF	Macrophage colony stimulating factor
	ph	Phosphorylation
	r	Reverse
	SD	Standard deviation
45	SDS	Sodium dodecyl sulfate
	TD	Tangier Disease
	TG	Triglycerides
	VA-HIT	Veterans Affairs Cooperative HDL Cholesterol Intervention Trial
	wt	Wild type

1. References cited

[0011]

1. Gordon, T., Castelli, W.P., Hjortland, M.C., Kannel, W.B., Dawber, T.R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. *Am. J. Med.* 1977; **62**: 707-14.

2. Kannel, W.B. High density lipoproteins: epidemiologic profile and risks of coronary artery disease. *Am. J. Cardiol.* 1983; **52**: 98-128.

3. Goldbourt, U., Yaari, S., Medalie, J.H. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. *Arterioscler. Thromb. Vasc. Biol.* 1997; **17**: 107-13.

4. Wilson, P.W.F., D'Agostino, R.B., Levy, D., Belanger, A.M., Silbershatz, H., Kannel, W.B. Prediction of coronary heart disease using risk factor categories. *Circulation.* 1998; **97**: 1837-47.

5. Genest, J., Jr., et al. Familial lipoprotein disorders in patients with premature coronary artery disease. *Circulation* 1992; **85**: 2025-33.

6. Genest, J., Jr., Bard, J.-M., Fruchart, J.-C., Ordovas, J.M., Schaefer, E.J. Familial hypoalphalipoproteinemia in premature coronary artery disease. *Arterioscler. Thromb.* 1993; **13**: 1728-37.

7. Heller, D.A., DeFaire, D., Pedersen, N.L., Dahlen, G., McClearn, G.E. Genetic and environmental influences

on serum lipid levels in twins. *N. Engl. J Med.* 1993; **328**: 1150-56.

8. Calabresi, L., Franceschini, G. High density lipoproteins and coronary heart disease: insights from mutations leading to low high density lipoprotein. *Curr. Opin. Lipidol.* 1997; **8**: 219-24.

9. Bodzioch, M., et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. *Nat. Genet.* 1999; **22**: 347-51.

5 10. Langmann T, Klucken J, Reil M, Liebisch G, Luciani MF, Chimini G, Kaminski WE, Schmitz G. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. *Biochem Biophys Res Commun* 1999; **257**:29-33

11. Brooks-Wilson, A., et al. Mutations in *ABC1* in Tangier disease and familial high-density lipoprotein deficiency. *Nat. Genet.* 1999; **22**: 336-45.

10 12. Rust, S., et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. *Nat Genet.* 1999; **22**: 352-55.

13. Remaley, A.T., et al. Human ATP-binding cassette transporter 1 (*ABC1*): Genomic organization and identification of the genetic defect in the original Tangier disease kindred. *Proc. Natl. Acad. Sci.* 1999; **96**: 12685-90.

15 14. Lawn, R.M., et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. *J. Clin. Invest.* 1999; **104**: R25-R31.

15 15. Brousseau, M.E., et al. Novel mutations in the gene encoding ATP-binding cassette 1 in four Tangier disease kindreds. *J. Lipid Res.* (in press).

20 16. Higgins CF. ABC transporters: from microorganisms to man. *Annu Rev Cell Biol* 1992; **8**:67-113

17. Higgins CF. Flip-flop: the transmembrane translocation of lipids. *Cell* 1994; **79**:393-5

18. van Helvoort A, Smith AJ, Sprong H, Fritzsche I, Schinkel AH, Borst P, van Meer G. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. *Cell* 1996; **87**:507-17

25 19. Dekkers DW, Comfurius P, Schroit AJ, Bevers EM, Zwaal RF. Transbilayer movement of NBD-labeled phospholipids in red blood cell membranes: outward-directed transport by the multidrug resistance protein 1 (MRP1). *Biochemistry* 1998; **37**:14833-7

20 20. Assmann G, Schmitz G & Brewer HB Jr. Familial high density lipoprotein deficiency: Tangier disease. In: Scriver C.R, Beaudet, AL, Sly, WS, Valle, D (eds): *The metabolic basis of inherited disease*. 6<sup>th</sup> ed., McGraw-Hill, New York Chapt 1989; **50**: 1267-1282.

25 21. Assmann, G., von Eckardstein, A., Brewer, H.B., Jr. Familial high density lipoprotein deficiency: Tangier disease. In *The Metabolic and Molecular Basis of Inherited Disease* (eds Scriver, C.R. et al.) 2053-2072 (McGraw-Hill, New York, 1995).

22. Serfaty-Lacroix, C., et al. Homozygous Tangier disease and cardiovascular disease. *Atherosclerosis* 1994; **107**: 85-98.

30 23. Schmitz G, Assmann G, Robenek H & Brennhausen B. Tangier disease: A disorder of intracellular membrane traffic. *Proc. Natl. Acad. Sci. USA* 1985; **82**: 6305-6309.

24. Rogler G, Trümbach B, Klima B, Lackner KJ & Schmitz G. High density lipoprotein-mediated efflux of newly synthesized cholesterol is impaired in fibroblasts from Tangier patients while membrane description and efflux of lysosomal cholesterol are normal. *Arterioscler. Thromb. Vasc. Biol.* 1995; **15**: 683-690.

35 25. Francis GA, Knopp RH & Oram JF. Defective removal of cellular cholesterol and phospholipids by apolipoprotein A-I in Tangier Disease. *J. Clin. Invest.* 1995; **96**: 78-87.

26. Luciani, M.F., Chimini, G. The ATP binding cassette transporter ABC1 is required for engulfment of corpses generated by apoptotic cell death. *EMBO J.* 1996; **15**: 226-35.

40 27. Hamon, Y., et al. Interleukin-1 $\beta$  secretion is impaired by inhibitors of the ATP binding cassette transporter, ABC1. *Blood* 1997; **90**: 2911-15.

28. Sakr SW, Williams DL, Stoudt GW, Phillips MC & Rothblat GH. Induction of cellular cholesterol efflux to lipid-free apolipoprotein A-I by cAMP. *Biochim. Biophys. Acta* 1999; **19**:1438:85-98.

45 29. Aslanidis C & Schmitz G. High speed apolipoprotein E genotyping and apolipoprotein B3500 mutation detection using real-time fluorescence PCR and melting curves. *Clin. Chem.* 1999; **45**: 1094-1097.

30 30. Aslanidis C, Nauck M & Schmitz G. High-speed prothrombin G A 20210 and methylenetetrahydrofolate reductase C T 677 mutation detection using real-time fluorescence PCR and melting curves. *Biotechniques* 1999; **27**: 234-236.

31. Bhakdi S, Dorweiler B, Kirchmann R, Torzewski J, Weise E, Tranum-Jensen J, Walev I, Wieland E. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. *J. Exp. Med.* 1995; **182**: 1959-1971.

50 32. Feinleib, M., Kannel, W.B., Garrison, R.J., McNamara, P.M., Castelli, W.P. The Framingham Offspring Study. Design and preliminary data. *Prev. Med.* 1975; **4**: 518-25.

33. Rubins, H.B., et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels

of high density lipoprotein cholesterol. *N. Engl. J. Med.* 1999; **341**: 410-18.

34. Wittwer, C.T., Ririe, K.M., Andrew, R.V., David, D.A., Gundry, R.A., Balis, U.J. The LightCycler: A microvolume multisample fluorimeter with rapid temperature control. *BioTechniques* 1997; **22**: 176-81.

5 35. Reiser, A., Geyer, M., van Miltenburg, R., Nauck, M., Tabiti, K. Mutation detection using multi-color detection on the LightCycler system. *Biochemica* 1999; **2**: 12-15.

36. Schaefer, E.J., et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. *J. Lipid Res.* 1994; **35**: 871-82.

10 37. McNamara, J.R., Schaefer, E.J. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. *Clin. Chim. Acta* 1987; **166**: 1-8.

38. Warnick, G.R., Benderson, J., Albers, J.J. Dextran sulfate-Mg<sup>2+</sup> precipitation procedure for quantitation of high-density lipoprotein cholesterol. *Clin. Chem.* 1982; **28**: 1379-88.

15 39. Friedewald, W.T., Levy, R.I., Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin. Chem.* 1972; **18**: 499-502.

40. Orso, E., Broccardo, C., Kaminski, W.E., Bottcher, A., Liebisch, G., Drobnik, W., Gotz, A., Chambenoit, O., Diederich, W., Langmann, T., Spruss, T., Luciani, M.F., Rothe, G., Lackner, K.J., Chimini, G., Schmitz, G. Transport of lipids from golgi to plasma membrane is defective in tangier disease patients and *Abc1*-deficient mice. *Nat. Genet.* 2000, **24**:192-196

10 41. Smythe, J.A., Symonds, G. Gene therapeutic agents: The use of ribozymes, antisense, and RNA decoys for HIV-1 infection. *Inflamm. Res.* 1995, **44**:11-15

**Description of Tables:**

**Table 1:**

25 **[0012] Summary of the characteristics of the study population consisting of 516 healthy blood donors.** Data are expressed as mean  $\pm$  SD. n indicates the number of analyzed individuals.

**Table 2:**

30 **[0013] Frequency of ABC1 polymorphisms G596A, A2589G, G3456C, and T1136C in healthy control subjects.** Genotyping was performed by LightCycler (Roche Diagnostics) PCR analysis. Data provide the relative percentage of homozygous, heterozygous or wild type individuals at the different polymorphic sites. n indicates the number of analyzed individuals.

35 **Table 3:**

**[0014] Distribution of G596A and A2589G polymorphisms in healthy control subjects.** Data represent absolute numbers of subjects with the respective allele combination. Data in parenthesis provide the relative percentage within each group.

**Table 4:**

40 **[0015] Amplification primers and hybridization probes for the LightCycler polymorphism analysis.** Hybridization probes are designated as detection (DET) or anchor (ANC) probes. As indicated, they are labeled with LightCycler-Red 640 or 705 and fluorescein, respectively. Phosphorylation (ph) of the 3'-end prevents the elongation of the detection probe. All detection probes recognize wild-type sequences, with the exception of the probe DET1136/mut. Fluo - fluorescein.

**Table 5:**

50 **[0016] Distribution of lipid and lipoprotein values in healthy individuals with different ABC1 polymorphisms.** HDL-C and ApoA-I levels in homozygous, heterozygous, and wild type male and female individuals are presented. Data are expressed as mean  $\pm$  SD. n indicates the number of analyzed individuals.

**Table 6:**

**[0017] Cholesterol and phospholipid efflux from mononuclear phagocytes isolated from healthy individuals homozygous for the wild type nucleotide at all four polymorphic sites and from healthy individuals ho-**

**mozygous for - the polymorphic allele at position 596 or 2589.** Lipid efflux is expressed as percent of basal unstimulated efflux observed in serum-free macrophage medium without ApoA-I. Data are the mean  $\pm$  SD of the indicated number (n) of different subjects. Efflux analysis for each subject was performed at least in quadruplicate. P values were calculated by independent Student T-test for wt/wt versus G596A and A2589G, respectively.

5

**Table 7:**

**[0018] Characteristics of FOS and VA-HIT subjects.** Results are listed as means  $\pm$  SD. \*Significantly different from male FOS control subjects, P<0.01.

10

**Table 8:**

**[0019] Genotype distribution of the ABC1 polymorphisms in FOS versus VA-HIT subjects.** Values in parentheses are expressed as a percentage of the total number of subjects within each group.

15

**Table 9:**

**[0020] Association of the G596A and A2589G ABC1 polymorphisms in FOS and VA-HIT subjects.** Data represent absolute numbers of subjects out of a total of 1,008 for FOS and 1,014 for VA-HIT, whereas values in parentheses (%) provide the relative percentage of subjects within each group (FOS or VA-HIT). Significant differences in proportions between FOS and VA-HIT are presented in bold face type.

20

**Table 10:**

25

**[0021] Association of the G596A and G3456C ABC1 polymorphisms in FOS and VA-HIT subjects.** Data represent absolute numbers of subjects out of a total of 1,006 for FOS and 1,014 for VA-HIT, whereas values in parentheses (%) provide the relative percentage of subjects within each group (FOS or VA-HIT). Significant differences in proportions between FOS and VA-HIT are presented in bold face type.

30

**Table 11:**

35

**[0022] Association of the A2589G and G3456C ABC1 polymorphisms in FOS and VA-HIT subjects.** Data represent absolute numbers of subjects out of a total of 1,008 for FOS and 1,014 for VA-HIT, whereas values in parentheses (%) provide the relative percentage of subjects within each group (FOS or VA-HIT). Significant differences in proportions between FOS and VA-HIT are presented in bold face type.

Table 1:

Summary of the characteristics of the study population consisting of 516 healthy blood donors.						
	n	Age	Cholesterol mmol/l	Triglycerides mmol/l	HDL-C mmol/l	LDL-C mmol/l
Men	274	27.3 $\pm$ 7.7	4.95 $\pm$ 1.13	1.23 $\pm$ 0.85	1.43 $\pm$ 0.35	2.97 $\pm$ 1.01
Women	242	30.5 $\pm$ 10.2	5.63 $\pm$ 1.10	1.19 $\pm$ 0.56	1.72 $\pm$ 0.45	3.24 $\pm$ 1.02

45

Table 2:

Frequency of ABC1 Polymorphisms in healthy control subjects				
	n	Homozygous	Heterozygous	Wild Type
<b>G596A</b>	511	8.0 %	43.5 %	48.5 %
<b>A2589G</b>	514	2.3 %	22.8 %	74.9 %
<b>G3456C</b>	516	0.0 %	5.0 %	95.0 %
<b>T1136C</b>	515	0.0 %	0.6 %	99.4 %

55

Table 3:

Distribution of G596A and A2589G Polymorphisms in healthy control subjects			
	G596A		
	596A/A	596G/A	596G/G
<b>A2589G</b>			
2589G/G	4 (9.8%)	6 (2.7%)	2 (0.8%)
2589A/G	14 (34.1%)	61 (27.6%)	39 (15.7%)
2589A/A	23 (56.1%)	154 (69.7%)	207 (83.5%)

Table 4:

Amplification primers and hybridization probes for the LightCycler polymorphism analysis	
G596A	
DET596/705	5'-LC Red 705-GCCTACCAAGGGAGAACTG-ph
ANC596	5'-CTTGGTGACCAAGAAGTTCTGAGCTTG-Fluo
FLA596-f	5'-TTTGCAAGGCTACCAAGTTACA
FLA596-r	5'-CAGGATTGGCTTCAGGATGT
T1136C	
DET1136/mut	5'-LC Red 640-ACTCCAGGCGAACAGACC-ph
ANC1136/B	5'-TTTCTGCGGTCCCTGGCTCCCCACC-Fluo
FLA1136-f	5'-AAGTCTGATGCAGACCAAGAGC
FLA1136-r	5'-CGGACAAGGTCCATTCTTG
A2589G	
DET2589rev	5'-LC Red 640-CTTCTGATATTCTCTTCTGG-ph
ANC2589rev	5'-TTAAAGAAAGAGCAGGAGGTCAACAGCACT-Fluo
FLA2589-f	5'-AGGCCCTGGTATTTCTTG
FLA2589-r	5'-CCCTGGAGTGGTTACAGT
G3456C	
DET3456rev	5'-LC Red 640-CGTGTCACTCTCATGGTCG-ph
ANC3456rev	5'-AGAAACCCCAGAGTCCTTACCGATGGTC-Fluo
FLA3456-f	5'-GGACAGTGTCTCAGAGCAG
FLA3456-r	5'-AGCAGCAAACCTTGAGTCAG

Table 5:

Distribution of lipid and lipoprotein values in healthy individuals with different ABC1 polymorphisms			
	Homozygous	Heterozygous	Wild Type
<b>G596A</b>	596A/A	596G/A	596G/G
<b>men</b>			
HDL-C (mmol/l)	n=19 1.41 ± 0.26	n=127 1.45 ± 0.36	n=126 1.41 ± 0.34
ApoA-I(g/l)	n=22 1.51 ± 1.6	n=95 1.49 ± 2.5	n=122 1.48 ± 2.3
<b>women</b>			
HDL-C (mmol/l)	n=22 1.82 ± 0.45	n=95 1.75 ± 0.46	n=122 1.73 ± 0.44
ApoA-I(g/l)	n=22 1.77 ± 3.9	n=95 1.79 ± 3.6	n=122 1.76 ± 3.3
<b>A2589G</b>	2589G/G	2589A/G	2589A/A
<b>men</b>	n=7	n=54	n=212

Table 5: (continued)

<b>Distribution of lipid and lipoprotein values in healthy individuals with different <i>ABC1</i> polymorphisms</b>			
	Homozygous	Heterozygous	Wild Type
A2589G	2589G/G	2589A/G	2589A/A
HDL-C (mmol/l)	1.50 ± 0.28	1.39 ± 0.32	1.44 ± 0.36
ApoA-I(g/l)	1.62 ± 21	1.47 ± 24	1.49 ± 24
<b>women</b>	n=5	n=63	n=173
HDL-C (mmol/l)	1.94 ± 0.40	1.80 ± 0.37	1.72 ± 0.48
ApoA-I(g/l)	2.02 ± 28	1.79 ± 32	1.76 ± 36
<b>G3456C</b>	3456C/C	3456G/C	3456G/G
<b>men</b>	n=0	n=15	n=228
HDL-C (mmol/l)		1.37 ± 0.27	1.44 ± 0.35
ApoA-I(g/l)		1.50 ± 26	1.49 ± 24
<b>women</b>	n=0	n=11	n=262
HDL-C (mmol/l)		1.84 ± 0.46	1.74 ± 0.45
ApoA-I (g/l)		1.79 ± 34	1.77 ± 35

Table 6:

<b>Cholesterol and phospholipid efflux from mononuclear phagocytes isolated from healthy individuals homozygous for the wild type nucleotide at all four polymorphic sites and from healthy individuals homozygous for the polymorphic allele at position 596 or 2589.</b>			
<b>A. Cholesterol efflux: ApoA-I [10 µg/ml]</b>			
	<b>wt/wt 596G/G; 2589A/A</b>	<b>596A/A</b>	<b>2589G/G</b>
<i>all probands</i>	128.7 ± 17.5% (n=18)	97.7 ± 22.4% (n=8; p<0.001)	103.4 ± 18.7% (n=11; p<0.001)
<i>men</i>	126.7 ± 16.6% (n=14)	98.8 ± 43.8% (n=2; n.s.)	104.5 ± 23.0% (n=6; p<0.025)
<i>women</i>	135.6 ± 21.4% (n=4)	97.3 ± 18.0% (n=6; p<0.001)	102.0 ± 14.3% (n=5; p<0.025)
<b>B. Cholesterol efflux: ApoA-I [10 µg/ml] + 24 h pretreatment with forskolin [10 µM]</b>			
	<b>wt/wt</b>	<b>596A/A</b>	<b>2589G/G</b>
	<b>596G/G; 2589A/A</b>		
<i>men and women</i>	121.8 ± 16.4% (n=12)	126.7 ± 37.4% (n=8; n.s.)	121.5 ± 38.8% (n=10; n.s.)
<b>C. Phospholipid efflux: ApoA-I [10 µg/ml]</b>			
	<b>wt/wt 596G/G; 2589A/A</b>	<b>596A/A</b>	<b>2589G/G</b>
<i>men and women</i>	125.9 ± 15.3% (n=18)	117.3 ± 27.1% (n=8; n.s.)	114.9 ± 32.6% (n=10; n.s.)
<b>D. Phospholipid efflux: ApoA-I [10 µg/ml] + 24 h pretreatment with forskolin [10 µM]</b>			
	<b>wt/wt 596G/G; 2589A/A</b>	<b>596A/A</b>	<b>2589G/G</b>
<i>men and women</i>	135.4 ± 20.2% (n=12)	136.7 ± 12.8% (n=8; n.s.)	124.5 ± 25.8% (n=10; n.s.)

Table 7:

Characteristics of FOS and VA-HIT subjects		
	FOS	VA-HIT
<b>N</b>	1014	1014
<b>Age (years)</b>	53±9	64±7*
<b>BMI (kg/m<sup>2</sup>)</b>	27.7±3.9	29±5*
<b>TC (mg/dL)</b>	206±36	175±25*
<b>LDL-C (mg/dL)</b>	136±33	111±23*
<b>HDL-C (mg/dL)</b>	44±12	32±5*
<b>TG (mg/dL)</b>	138±101	161±68
<b>TC:HDL-C</b>	5.1±1.6	5.7±1.1*

\*Significantly different from male FOS control subjects, P<0.01.

Table 8:

Genotype distribution of the <b>ABC1</b> polymorphisms in FOS versus VA-HIT subjects				
Mutation	FOS	VA-HIT	P	
<b>G596A</b>				
Total n	1013	1014		
GG (%)*	543 (53.6)	454 (44.8)		
GA (%)	402 (39.7)	484 (47.7)		
AA (%)	68 (6.7)	76 (7.5)		
<b>A Allele frequency</b>	<b>0.266</b>	<b>0.314</b>	<b>0.000</b>	
<b>A2589G</b>				
Total n	1014	1014		
AA (%)	779 (76.8)	707 (69.7)		
AG (%)	222 (21.9)	285 (28.1)		
GG (%)	13 (1.3)	22 (2.2)		
G Allele frequency	0.122	0.162	0.001	
<b>G3456C</b>				
<b>Total n</b>	<b>1013</b>	<b>1014</b>		
GG (%)	965 (95.3)	940 (92.7)		
GC (%)	43 (4.2)	70 (6.9)		
CC (%)	5 (0.5)	4 (0.4)		
C Allele frequency	0.026	0.038	0.032	

5

10

15

20

25

30

35

40

45

50

55

Table 9:

Association of the G596A and A2589G <i>ABC1</i> polymorphisms in FOS and VA-HIT subjects						
			G596A			
	GG		GA		AA	
	<u>FOS</u>	<u>VA-HIT</u>	<u>FOS</u>	<u>VA-HIT</u>	<u>FOS</u>	<u>VA-HIT</u>
A2589G						
AA	459 (45.6)	360 (35.5)	77 (7.6)	89 (8.8)	5 (0.5)	5 (0.5)
AG	268 (26.6)	30 (30.2)	125 (12.4)	166 (16.4)	5 (0.5)	12 (1.2)
GG	47 (4.7)	41 (4.0)	18 (1.8)	30 (3.0)	3 (0.3)	5 (0.5)

Table 10:

Association of the G596A and G3456C <i>ABC1</i> polymorphisms in FOS and VA-HIT subjects						
	G596A					
	GG		GA		AA	
	<u>FOS</u>	<u>VA-HIT</u>	<u>FOS</u>	<u>VA-HIT</u>	<u>FOS</u>	<u>VA-HIT</u>
G3456C						
GG	508 (50.5)	426 (42.0)	27 (2.7)	26 (2.6)	3 (0.3)	2 (0.2)
GC	384 (38.2)	450 (44.4)	14 (1.4)	34 (3.4)	2 (0.2)	0 (0)
CC	66 (6.6)	64 (6.3)	2 (0.2)	10 (1.0)	0 (0)	2 (0.2)

Table 11:

Association of the A2589G and G3456C <i>ABC1</i> polymorphisms in FOS and VA-HIT subjects						
	A2589G					
	AA		AG		GG	
	<u>G3456C</u>					
GG	746 (74.0)	666 (65.7)	204 (20.2)	257 (25.3)	11 (1.1)	17 (1.7)
GC	26 (2.6)	39 (3.8)	15 (1.5)	27 (2.7)	1 (0.1)	4 (0.4)
CC	3 (0.3)	2 (0.2)	2 (0.2)	1 (0.1)	0 (0)	1 (0.1)

Description of specific embodiments**Identification of four polymorphisms in the gene encoding the human ATP-binding cassette transporter 1 (ABC1) and association of these polymorphisms with decreased ApoA-I mediated efflux of cholesterol**

**[0023]** This invention provides the four polymorphisms G596A, T1136C, A2589G, and G3456C in the *ABC1* gene (*ABC1* gene see Figures 1 and 2), which affect the primary structure of the gene product. The frequencies of these *ABC1* polymorphisms were determined in a young and healthy population (Example 1).

**[0024]** The two most common polymorphisms (G596A and A2589G) are both associated with a decreased in vitro ApoA-I mediated efflux of cholesterol from mononuclear phagocytes, which is a typical feature of Tangier disease (Example 2).

**[0025]** No association of any of the polymorphisms were found with HDL-cholesterol, ApoA-I or any other lipoprotein fraction probably because the effect of the *ABC1* polymorphisms on the protein function is compensated by other factors controlling plasma HDL levels (Example 2 and 4)

**[0026]** The precise mechanism by which *ABC1* promotes cellular lipid efflux is not completely defined. However, recently we could show that *ABC1* is expressed on the plasma membrane and the Golgi complex, mediates ApoA-I associated export of cholesterol and phospholipids from the cell, and is regulated by cholesterol flux. Also, our results indicate that *ABC1* is involved in lipid export processes involving vesicular budding between the Golgi and the plasma membrane. In addition to a possible function as direct lipid transporter, *ABC1* may also be involved in the initiation of signal transduction processes stimulating intracellular lipid transport pathways (40). The finding that pretreatment of monocytes with forskolin, an cAMP elevating agent known to stimulate ApoA-I dependent lipid efflux (28), was able to normalize cholesterol and phospholipid efflux in 596A/A and 2589G/G subjects, may indicate that these gene variants affect the *ABC1* function, which is related both to signaling and lipid transport. Since such a defect could be overcome by regulatory signals, this hypothesis may also provide a possible explanation for the lack of an effect on serum HDL levels.

**[0027]** In summary, these data emphasizes the role of *ABC1* in lipid efflux, the first step in reverse cholesterol transport, and can be taken as evidence that common polymorphisms in *ABC1* directly affect cellular lipid homeostasis, which is a key factor in the atherogenetic process.

**Frequencies of the identified *ABC1* gene polymorphisms in men with low HDL cholesterol levels and coronary heart disease**

**[0028]** The frequencies of three of the common single nucleotide polymorphisms in *ABC1* (G596A, A2589G, and G3456C) were found to be significantly increased in the population comprised of men having HDL deficiency and established CHD (participants enrolled in the Veterans Affairs Cooperative HDL Cholesterol Intervention Trial ,VA-HIT) relative to control subjects from the Framingham Offspring Study (FOS). Moreover, associations were observed between *ABC1* polymorphisms and status, indicating that wild type alleles were consistently more prevalent in FOS than in VA-HIT but that mutant alleles were consistently more prevalent in VA-HIT (Example 3).

**[0029]** In summary, these data demonstrate that three of the common variants in the gene encoding *ABC1* occur with significantly increased frequency in a population of men having low HDL-C as their primary lipid abnormality and established CHD. These results indicate that common mutations in the *ABC1* play a role in the development of CHD in the general population. These data also provide evidence for a role of *ABC1* in the premature CHD associated with common HDL deficiency states. All three *ABC1* variants are either conserved between human and mouse or are very similar as in the case of A2589G (isoleucine and valine, respectively), suggesting that each has an important functional role.

**[0030]** Furthermore, the identification of *ABC1* as a transporter for IL-1 $\beta$  identifies this gene as a candidate gene for treatment of inflammatory diseases including rheumatoid arthritis and septic shock (27). The cytokine IL-1 $\beta$  is a broadly acting proinflammatory mediator that has been implicated in the pathogenesis of these diseases.

**[0031]** Moreover, we could demonstrate, that glyburide as an inhibitor of IL-1 $\beta$  secretion inhibits not only Caspase I mediated processing of pro-IL-1 $\beta$  and release of mature IL-1 $\beta$  but simultaneously inhibits ceramide formation from sphingomyelin mediated by neutral sphingomyelinase and thereby releases human fibroblasts from G<sub>2</sub>-phase cell cycle arrest. These data provide a further mechanism indicative for a function of *ABC1* in signalling and cellular lipid metabolism.

**[0032]** Autoimmune disorders that are associated with the antiphospholipid syndrome (e.g. lupus erythematoses) can be related to dysregulation of B-cell and T-cell function, aberrant antigen processing, or aberrations in the asymmetric distribution of membrane phospholipids. ABC-transporters are, besides their transport function, candidate genes for phospholipid translocases, floppases and scramblases that regulate phospholipid asymmetry (outer leaflet: PC+SPM; inner leaflet: PS+PE) of biological membranes [11]. There is considerable evidence for a dysregulation of

members of the ABC-transporter family in patient cells. We conclude that these ABC-cassettes are also candidate genes for a genetic basis of antiphospholipid syndromes such as in Lupus erythematoses.

[0033] In summary, our findings emphasize how insight into the pathophysiology of a major disease process may be gleaned from a very rare genetic disorder.

5 [0034] Lipid disorders represent diseases characterized by changes in the lipid- and lipoproteinconcentrations in the organism. Cardiovascular diseases represent diseases of the heart and vessel system including coronary heart disease and atherosclerosis. Inflammatory diseases include diseases such as psoriasis and lupus erythematoses.

10 [0035] This invention is directed to the nucleotide sequences of the identified *ABC1* polymorphism variants, the corresponding protein sequences, antibodies, pharmaceutical compositions, diagnostic tests, vectors, and vector host systems according to the claims.

[0036] Our findings identify *ABC1* as a target for the diagnosis of lipid disorders, cardiovascular diseases , and inflammatory diseases.

[0037] Our findings further identify *ABC1* as a target for therapeutic strategies aimed at the prevention of lipid disorders, cardiovascular diseases, and inflammatory diseases.

15 [0038] The identified *ABC1* polymorphisms may create immunogenic protein sites that can be used for the generation of antibodies. These antibodies can be used for the detection of mutated *ABC1*-protein and can be used for the diagnosis of lipid disorders, cardiovascular diseases, and inflammatory diseases.

20 [0039] Therapeutic strategies also include the gene therapy of lipid disorders, cardiovascular diseases, and inflammatory diseases. For this gene therapy, a polynucleotid consisting of a transcription unit is used. The transcription unit consists of at least 9 consecutive nucleotides that are identical or substantial similar to the *ABC1* cDNA sequence. Alternatively, the transcription unit consists of at least 9 consecutive nucleotides leading to the production of antisense RNA of wild type *ABC1* or *ABC1* containing one or more of the identified polymorphisms. The transcription unit is combined with heterologous transcription regulating sequences, which regulate the transcription in human cells. The heterologous transcription regulating sequences include a promoter that is constitutively active in human cells. Alternatively, the heterologous transcription regulating sequences can contain a promoter that can be induced or repressed in human cells by the addition of a regulatory substance.

25 [0040] Another therapeutic approach would be the application of antisense molecules or ribozymes or RNA decoys directed towards the *ABC1* transcripts resulting in a modulation of the *ABC1* expression. The methodology has been reviewed in (41).

30 [0041] This invention also includes a vector containing the above described transcription unit and transcription regulating sequences. Preferred vector is a virus, e.g. retrovirus, adenovirus, adeno-associated virus, herpes simplex virus, lentivirus, vaccinia virus, sindbis virus, semliki forest virus.

[0042] Preferred vectors are also plasmids.

35 [0043] The invention also includes a pharmaceutical preparation that contains the recombinant vectors, e.g. in a colloidal dispersion system. Preferred colloidal dispersion systems are liposomes or polylysine ligands.

[0044] The invention also includes pharmaceutical compositions that contain the above described recombinant vector constructs in combination with nontoxic, inert, pharmaceutically-suited carrier substances. Application of these pharmaceutical compositions can be locally or systemically (e.g. intravenous, intraarterious, intramuscular, subcutane, intradermal, anal, vaginal, nasal, transdermal, intraperitoneal, oral, or as aerosol).

40 [0045] The invention further includes recombinant host cells, especially recombinant eucaryotic host cells, that contain the above described recombinant vector constructs.

### Examples

#### 45 Example 1

##### **ATP-binding cassette transporter 1 (*ABC1*) gene polymorphisms**

##### 50 **Complete cDNA sequence of human *ABC1***

[0046] We have cloned the complete cDNA sequence of human *ABC1*(10). The nucleotide sequence of the complete coding region of the human *ABC1* gene is shown in Fig. 1. The open reading frame of 6603 bp encodes a 2201 amino acid protein with a predicted molecular weight of 220 kDa. The protein sequence of the human *ABC1* gene is shown in Fig. 2.

##### 55 **Identification of four polymorphisms in human *ABC1***

[0047] Complete sequence analysis (by dye primer sequencing ?) of human *ABC1* in different (how many ?)Tangier

kindred's revealed several polymorphisms, which were also found in healthy control subjects. These are G596A, T1136C, A2589G, and G3456C. All of them change the amino acid sequence of ABC1 and therefore may affect the function of this transporter.

5 **Frequency of polymorphisms in the general population**

[0048] In order to determine the frequency of these four polymorphisms in the general population, we have tested 516 healthy blood donors. Table 1 summarizes the characteristics of the blood donors. The allele frequencies shown in table 2 demonstrate that G596A, A2589G and G3456C variants are quite common in a young, healthy population.

10 The G596A polymorphism had the highest prevalence with an estimated frequency of 29.8% for the minor allele (596A), followed by A2589G with 13.7% (2589G), and G3456C with 2.5% (3456C). There was no significant deviation from the Hardy-Weinberg equilibrium. Only only 3 heterozygotes were found for T1136C in our group.

[0049] When we further analyzed the distribution of the polymorphisms in healthy blood donors, we detected a frequent coincidence of the G596A and A2589G polymorphisms (table 3). In homozygote individuals for the minor G596A 15 allele (596A/A; n=41) the frequency of the alleles A and G of the A2589G polymorphism was 73.2% and 26.8% respectively, while in homozygotes for the major G596A allele (596G/G; n=248) the frequencies were 91.3% and 8.7% (p < 0.001). This indicates that the two mutations are in linkage disequilibrium in our population. While there was apparently no linkage disequilibrium between G596A and G3456C, the numbers were too small to exclude this with certainty (data not shown).

20 **Methods**

[0050] *Sample collection.* Study subjects were recruited from healthy blood donors at the Institute for Clinical Chemistry (department of transfusion medicine) at the University of Regensburg. Samples from 516 individuals who gave 25 consent to genetic analysis at the time of recruitment were available for the study. At the day of sample collection lipid parameters were determined and DNA-extraction was performed. A local review committee approved the Sample collection for genetic analysis.

[0051] *DNA extraction.* All DNA samples were isolated from whole blood with a QIAamp DNA Blood Maxi Kit (Qiagen) according to the manufacturer's recommendations.

[0052] *Detection of polymorphisms.* Genotype analysis was performed on the LightCycler (Roche Diagnostics) as previously described, with minor modifications (29,30). The amplification primers and hybridization probes are listed in table 4. The latter are designated as detection or anchor probes. They are labeled with LightCycler-Red 640 or 705 and fluorescein, respectively. We performed 40 amplification cycles under the following conditions: denaturation at 95°C for 120 s in the first step and 0 s in all subsequent steps, annealing at 57°C for 10 s, extension at 72°C for 15 s. 35 This was followed by a temperature gradient melting curve analysis as described elsewhere (29,30). All detection probes recognize wild-type sequences, with the exception of the probe DET1136/mut, which is complementary to the sequence of the minor allele, i.e. 1136C. In order to assure specificity and accuracy of the LightCycler analysis 100 randomly selected samples were subjected to automated sequencing (ABI Prism 310 Genetic Analyzer), which proved full concordance of the results.

[0053] *Statistical Analysis.* To compare allele frequencies we employed chi-square test.

**Example 2**

45 **ABC1 gene polymorphisms are associated with impaired ApoA-I mediated cholesterol efflux but not with decreased serum HDL or ApoA-1**

[0054] In Tangier patients, mutations in *ABC1* are associated with severely decreased HDL-cholesterol and a lack 50 or marked reduction of ApoA-I induced cholesterol and phospholipid efflux. Therefore, we hypothesized that HDL-cholesterol and ApoA-I levels as well as cholesterol and phospholipid efflux might differ between homozygous wild-type genotypes and carriers of one of the polymorphisms. Since the T1136C polymorphism was only found in heterozygous form in three individuals we did not include T1136C in our statistical analysis.

55 **Analysis of the association of the identified ABC1 gene polymorphisms with HDL-cholesterol, ApoA-I, or other lipoprotein fractions**

[0055] We first analyzed the distribution of lipid and lipoprotein values in individuals with different genotypes. As indicated in table 5 neither heterozygous nor homozygous carriers of the G596A, A2589G, or G3456C polymorphisms had significantly different HDL-cholesterol or ApoA-I levels compared to the homozygous wild type probands. We also

analyzed further parameters of plasmatic lipoprotein metabolism, even though this was not an a priori hypothesis. Total plasma cholesterol, triglycerides, and LDL-cholesterol were also not significantly different among the various genotypes.

5 **Analysis of the association of the identified *ABC1* gene polymorphisms with cholesterol and phospholipid efflux**

[0056] We then analyzed cholesterol and phospholipid efflux from mononuclear phagocytes isolated from individuals homozygous for the wild type nucleotide at all four polymorphic sites and from individuals homozygous for the polymorphic allele at position 596 or 2589. Monocytes from subjects homozygous for at least one polymorphic allele were found to have a highly significant reduction in ApoA-I mediated cholesterol efflux (table 6 A). Whereas in cholesterol loaded monocytes from wild type individuals ApoA-I incubation for 17 hrs increases cholesterol efflux to approximately 130% of baseline values, no stimulation of efflux was observed in subjects homozygous for G596A (596A/A) or A2589G (2589G/G). This finding was independent of gender. In order to investigate, whether the lack of cholesterol efflux could be overcome by regulatory mechanisms, cells were pre-incubated with forskolin, a cAMP-elevating agent, which is known to stimulate ApoA-I mediated lipid efflux (28). As shown in table 6 B forskolin treatment normalized cholesterol efflux in subjects with polymorphic alleles.

[0057] A tendency towards reduced ApoA-I mediated efflux of choline containing phospholipids was also correlated with the presence of both variant alleles but did not reach statistical significance (table 6 C). Similar to the ApoA-I mediated cholesterol efflux, forskolin pretreatment abolished the differences between wild type and 596A/A or 2589G/G, respectively (table 6 D).

**Methods**

25 [0058] *Lipids and Lipoproteins.* Venous blood was taken from all blood donors after a 12-h fast. The samples were obtained in polypropylene tubes, centrifuged at 4000 x g for 10 min. Cholesterol, triglycerides, and HDL-cholesterol was measured by standard clinical chemistry protocols as previously described. LDL cholesterol was calculated by the Friedewald equation. ApoA-I was determined on a BNA nephelometer (Dade-Behring) with reagents from Dade-Behring.

30 [0059] *Cellular Lipid Efflux.* Human peripheral blood cells were isolated from lithium-heparin treated blood samples of adult, healthy volunteers. The peripheral blood mononuclear cell fraction was separated by density gradient centrifugation over Ficoll-Histopaque 1.007 (Sigma). Cells positive for CD2, CD7, CD16, CD19 and CD56 were removed by appropriate magnetic beads (Dynal) leaving > 80% pure monocytes. Isolated monocytes were then cultured at a density of  $1.5 \times 10^5$  cells/mL in polystyrene culture dishes (100x15mm Petri dish, Falcon) in a serum-free macrophage medium (Macrophage-SFM, Gibco Life Technologies) supplemented with 50ng/mL human recombinant M-CSF (R&D Systems). After an overnight incubation cells were cholesterol loaded for 24 hrs by addition of enzymatically modified LDL (E-LDL; 40  $\mu$ g/ml), which was prepared as previously described (31). The incubation medium was further supplemented with  $^{14}\text{C}$ -cholesterol (1.5  $\mu$ Ci/ml) and  $^{3}\text{H}$ -choline (10 $\mu$ Ci/ml) in order to label cellular cholesterol and choline containing phospholipids. In a subset of experiments cells were stimulated with 10  $\mu$ M forskolin during the labeling period. After 40 24 hrs monocytes were washed and incubated for 17 hrs with or without 10  $\mu$ g/ml ApoA-I (Sigma) in macrophage medium containing 0.1 % bovine serum albumin and 50ng/mL M-CSF. After incubation the media were removed and centrifuged at 800 x g to precipitate any detached cells. Cells were lysed in 0.2% SDS. Lipids were extracted by liquid extraction according to the method of Bligh and Dyer (13).  $^{3}\text{H}$  and  $^{14}\text{C}$  radioactivities of the total lipid extracts were measured by liquid scintillation counting in order to distinguish between  $^{3}\text{H}$  labeled phospholipids and  $^{14}\text{C}$ -cholesterol.

45 Lipid efflux was calculated as percentage of disintegrations per minute (dpm) in medium divided by the sum of dpm recovered from medium and cells. The ApoA-I specific efflux is expressed a percent of basal unstimulated efflux observed in serum-free macrophage medium without ApoA-I.

[0060] *Statistical Analysis.* For comparison of lipid parameters and efflux data between wild type and polymorphisms the two-sample t test was used.

50 **Example 3**

**Frequencies of the identified *ABC1* gene polymorphisms in men with low HDL cholesterol levels and coronary heart disease**

55 [0061] To address the question whether the identified polymorphisms in *ABC-1* can provide insight into common HDL deficiency states and CHD risk, we compared the frequencies of three common *ABC1* variants (G596A, A2589G, and G3456C) between two different populations.

[0062] One population consisted of men participating in the Framingham Offspring Study (FOS), a long-term prospective evaluation of cardiovascular disease risk factors (32), whereas the other population consisted of men enrolled in the Veterans Affairs Cooperative HDL Cholesterol Intervention Trial (VA-HIT). VA-HIT, a multicenter study initiated in 1991, was designed to address the hypothesis that increasing HDL-C levels with gemfibrozil therapy would reduce the incidence of death from CHD and nonfatal myocardial infarction in men with established CHD, who had reduced HDL-C concentrations ( $\leq 40$  mg/dL; 1 mmol/L) and normal LDL-C levels (33). The characteristics of these two groups are provided in table 7. Men participating in VA-HIT were older, and slightly heavier, than men in FOS. With respect to plasma lipids, men in VA-HIT had significantly lower concentrations of plasma total cholesterol (-15%), HDL-C (-27%), and LDL-C (-18%), with the greatest difference between the groups noted in HDL-C levels. These differences resulted in a TC:HDL-C ratio which was significantly increased in VA-HIT relative to FOS in control subjects from the FOS with those of participants in the VA-HIT.

#### Screening of the FOS and VA-HIT populations for the presence of the identified *ABC1* polymorphisms

[0063] In order to test the hypothesis that *ABC1* polymorphisms may play a role in common HDL deficiency states and, ultimately, CHD risk, genomic DNA from 1,014 men per FOS and VA-HIT population, respectively, was screened for the presence of three common single nucleotide polymorphisms in the *ABC1* gene (G596A, A2589G, and G3456C), using sequence-specific primers with the LightCycler System. The frequency distribution of each *ABC1* polymorphism in the FOS and VA-HIT populations is provided in table 8. With regard to the G596A polymorphism, the frequency of the mutant A allele was significantly increased ( $P=0.000$ ) in VA-HIT subjects (0.314) relative to FOS (0.266), translating into fewer wild type, but more heterozygous, individuals in the former group. This was similarly the case for the A2589G mutation in which the mutant G allele frequency was 0.162 in VA-HIT versus 0.122 in FOS ( $P<0.001$ ). The G3456C polymorphism was rare in both the FOS and VA-HIT populations; however, a significant increase ( $P<0.032$ ) in the frequency of the mutant C allele was observed in VA-HIT subjects (0.038 vs. 0.026). Thus, the frequency of each of these single nucleotide polymorphisms was significantly increased in a population comprised of men having HDL deficiency and established CHD.

#### Analysis of the associations between each *ABC1* polymorphism and status

[0064] We further evaluated these data for the presence of associations between each *ABC1* polymorphism and status. Associations between the G596A and A2589G, G596A and G3456C, and A2589G and G3456C *ABC1* variants in FOS and VA-HIT subjects are presented in tables 9-11, respectively. In each case, a significantly greater proportion of FOS subjects possessed a pair of wild type alleles relative to VA-HIT subjects. In contrast, a significantly greater proportion of VA-HIT subjects possessed either one or two mutant alleles for each *ABC1* variant. These data indicate that wild type alleles were consistently more prevalent in FOS than in VA-HIT, with mutant alleles consistently more prevalent in VA-HIT relative to FOS, suggesting that the occurrence of these *ABC1* variants may be linked.

#### Methods

[0065] *Subjects.* Subjects were men participating in either the Framingham Offspring ( $n=1,014$ ) or VA-HIT ( $n=1,014$ ) studies. The design and methods for FOS have been described elsewhere in detail (32), as have the rationale, design, and results of the VA-HIT study (33). FOS subjects were participants in cycle 4 of FOS and were free of clinical evidence of CHD. For VA-HIT, men were recruited at 20 Veterans Affairs medical centers throughout the United States. Eligibility for the trial required a documented history of CHD, an age of  $<74$  years, an absence of coexisting conditions, an HDL-C level of  $\leq 40$  mg/dL (1.0 mmol/L), an LDL-C of  $\leq 140$  mg/dL (3.6 mmol/L), and a triglyceride level of  $<300$  mg/dL (3.4 mmol/L). Since DNA was available from 1,014 men participating in the VA-HIT study, an equal number of men participating in cycle 4 of FOS was randomly selected from a total of 1,139 samples available for analysis. Informed consent was obtained from all subjects. Nearly all of the subjects in both groups were Caucasians. Information on alcohol consumption, smoking, blood pressure, body mass index (BMI), and diabetes were available for all subjects enrolled in these studies. Plasma lipid and lipoprotein data used in our analyses were obtained from FOS subjects who were not taking a lipid-lowering medication, while those from the VA-HIT subjects were obtained at baseline, prior to randomization to a treatment (gemfibrozil, 600 mg bid) or placebo group.

[0066] *DNA Isolation.* Genomic DNA was extracted from whole blood samples using either QIAamp mini kits (Qiagen) or Generation Capture Column® kits (Gentra Systems).

[0067] *Mutation detection.* Genotype analysis was performed using LightCycler technology (Roche Diagnostics), as described elsewhere in detail (28,34,35). Briefly, this method enables recognition of alterations in a nucleotide sequence through the detection of changes in fluorescence emission, dependent upon energy transfer between fluorophores on two adjacent hybridization probes. Both probes recognize the sequence of a specific amplicon. The de-

tection probe, labeled on its 5' end with LightCycler-Red 640 or 705, overlaps the site of a polymorphic nucleotide, whereas the anchor probe, carrying fluorescein at the 3' end, binds to the amplicon 1 to 3 nucleotides upstream of the detection probe. After PCR in the presence of target DNA, samples are briefly denatured at 95°C, rapidly cooled to 35-40°C, and, in the final step, heated gradually to 70-80°C. Differentiation between a wild type and polymorphic allele is possible, because the detection probe will detach at a different melting temperature dependent upon the presence of a mismatch between the probe and amplicon sequences.

**[0068]** *Statistical analyses.* To compare the FOS and VA-HIT populations, we employed chi-square tests for categorical measures and two-sample t test for continuous measures, using the SYSTAT statistical package.

10 **Example 4**

**Analysis of the associations between each *ABC1* polymorphism and plasma lipid profiles in FOS**

**[0069]** Analyses were also performed to test for potential associations between each *ABC1* polymorphism and plasma lipid profiles in FOS. Because the VA-HIT subjects were selected primarily on the basis of plasma lipid values and CHD, we did not test for associations in this group, which was, by design, more homogeneous than that of FOS. In FOS, no statistically significant relationships were detected between any of the 3 *ABC1* polymorphisms and plasma lipids (data not shown). This remained the case after adjustment for familial relationships, age, BMI, smoking, alcohol intake, and apolipoprotein E genotype. Although this result is somewhat incongruous with evidence for a role of *ABC1* in the regulation of plasma HDL-C levels (9,11-15), we believe that *ABC1* polymorphisms may directly influence intracellular cholesterol trafficking and, ultimately, reverse cholesterol transport. Support for this hypothesis is provided by the results presented in *Example 2* demonstrating that the homozygosity for either the G596A or A2589G polymorphism is associated with decreased cellular cholesterol efflux in healthy, young subjects. Moreover, because HDL-C levels are modulated by other genetic and environmental factors (7, 36), direct effects of *ABC1* polymorphisms on plasma HDL-C concentrations may not be readily apparent, especially in the heterozygous state.

**Methods**

**[0070]** *Measurement of plasma lipids and lipoproteins.* Blood samples were collected from subjects, after a 12-14 h fast, into tubes containing 0.1% EDTA. Plasma was isolated and frozen for subsequent analysis of plasma lipid and lipoprotein concentrations. Plasma total cholesterol and triglyceride concentrations were determined using enzymatic assays (37). Plasma HDL-C concentrations were measured after dextran sulfate-magnesium precipitation of apoB-containing lipoproteins (38), and LDL-C levels were calculated with the equation of Friedewald, Levy, and Fredrickson (39).

**[0071]** *Statistical analyses.* To evaluate the relationships between *ABC1* genotype and plasma lipids, we used analysis of covariance techniques, employing several different models to adjust for potential confounders. Age, BMI, smoking status, alcohol consumption, and apolipoprotein E genotype were included in these models. Loglinear models were used to examine associations between the 3 polymorphisms and status (FOS or VA-HIT). For all 3 models, statistically significant interactions were detected between *ABC1* genotype and status, indicating that differences existed between the FOS and VA-HIT groups with regard to the presence of mutant alleles. Specifically, for each *ABC1* polymorphism, those in the FOS group were more likely to be categorized as wild type, whereas VA-HIT subjects were more likely to be classified as heterozygous.

45

50

55

## SEQUENCE LISTING

&lt;110&gt; Bayer AG

5           <120> ATP binding cassette transporter 1 (ABC1) gene  
           polymorphisms and uses thereof for the diagnosis  
           and treatment of lipid disorders, cardiovascular  
           diseases and inflammatory diseases

10           <130> ATP binding cassette transporter 1 (ABC1) gene

15           <140>  
           <141>

15           <150> 101706  
           <151> 1998-09-25

15           <160> 2

170           <170> PatentIn Ver. 2.0

20           <210> 1  
           <211> 6880  
           <212> DNA  
           <213> Human

25           <220>  
           <223> cDNA of ABCA1 (ABC1)

30           <400> 1  
           caaacatgtc agctgttact ggaagtggcc tggcctctat ttatcttcct gatcctgate 60  
           tctgttcggc tgagctaccc accctatgaa caacatgaat gccattttcc aaataaagcc 120  
           atgccctctg caggaacact tccttgggtt caggggattt tctgtatgc caacaacccc 180  
           tgttccgtt acccgactcc tggggaggct cccggagttt ttggaaactt taacaaatcc 240  
           attgtggctc gcctgttctc agatgtcg aggcttcttt tatacagcca gaaagacacc 300  
           agcatgaagg acatgcgcaa agttctgaga acattacagg agatcaagaa atccagctca 360  
           aacttgaagc ttcaagattt cctggggac aatgaaacct tctctgggtt cctgtatcac 420  
           aacctctctc tcccaaaggc tactgtggac aagatgtctga gggctgtatgt cattctccac 480  
           aaggatatttt tgcaaggcta ccagttacat ttgacaaggctc tgcataatgg atcaaaatca 540  
           gaagagatgttcaacttgg tgaccaagaa gtttctgac tttgtggcc accaaggag 600  
           aaatggctg cagcagagcg agtacttcgt tccaaatgg acatctggaa gccaatctcg 660  
           agaacactaa actctacatcccttcccg agcaaggaggc tggccggc cacaaaaaaca 720  
           ttgctgcata gtcttgggac tctggcccgag gagctgttca gcatgagaag ctggagtgc 780  
           atgcgacagg aggtgtatgtt tctgaccaat gtgaacagct ccagctctc cacccaaata 840  
           taccaggctg tgcataatgg tgcataatgg catcccgagg gaggggggct gaagatcaag 900  
           tctctcaact ggtatgagga caacaactac aaagccctct ttggaggcaa tggcactgag 960  
           gaagatgtctg aaacccctca tgacaaactct acaactcctt actgcaatga tttgtatgaag 1020  
           aatttggagt ctgttcctt ttcccccattt atctggaaag ctctgaagcc gctgctcggtt 1080  
           ggaaagatcc tgcataccacc tgacactcca gccacaaggc aggtgtatggc tgaggtgaac 1140  
           aagacccctcc aggaacttggc tgcataatgg gatctggaa gcatgtggga ggaactcagc 1200  
           cccaagatcttccat ggacccatggc ggagaacaggc caagaaatgg accttgcgtt gatgtgttgc 1260  
           gacacgggg acaatgacca cttttggaa cagcagttgg atggcttgc ttggacagcc 1320  
           caagacatcg tggcggtttt ggccaaagcac ccagaggatg tccagttccag taatgggttct 1380  
           gtgtacacctt ggagagaagg ttcaacaggactaaccagg caatccggac catatctcg 1440  
           ttcatggagt gtgtcaacctt gaacaagcttca gaacccatgg caacagaatgt ctggctcatc 1500  
           aacaagtccat tggagctgtt ggtatgagagg aagttctggg ctggattgtt gttcaactgg 1560  
           attactccatcg gcagcattttt gctgccttcatgttcaatgtt acaagatcccg aatggacatt 1620  
           gacaatgttgg agaggacaaa taaaatcaag gatgggtactt gggaccctgg tcctcgagct 1680  
           gacccttttgg aggacatcggtt gtcgttgcggggggcttcg cttacttgc ggtatgtgg 1740  
           gagcaggcaat tcatcgatgtt gtcgtacgggc accggagaaga aaaaactgtgtt ctatatgca 1800  
           cagatgccttccat tgcacgttgc ctggattttac tcagttggctt gatcatcaaa gggcatctgt 1860  
           cccctcttca tgcacgttgc ctggattttac tcagttggctt gatcatcaaa gggcatctgt 1920  
           tatgagaagg aggacacggctt gaaagagacc atgcggatca tggcctggaa caacagcatc 1980  
           ctctggtttacatgttgccttccat tgcacgttgc ctggattttac tcagttggctt gatcatcaaa gggcatctgt 2040

5	gtggcatacc	tgaagtttag	aaacctgctg	ccctacagtg	atccccagcg	gggtttgtc	2100
	ttccctgtccg	tgtttgcgt	ggtgacaatc	ctgcagtgct	tcctgattag	cacactctc	2160
	tccagagcca	acctggcagc	agcctgtggg	ggcatcatct	acttcacgt	gtacctgccc	2220
	tacgtcttgt	gtgtggcatg	gcaggactac	gtgggcttca	caactcaagat	cttcgcttagc	2280
	ctgctgtctc	ctgtggctt	tggggttggc	tgtgagtgact	ttggcccttt	tgaggagcag	2340
	ggcattggag	tgcgatggga	caacctgttt	gagagtccctg	tggaggaaga	tggcttcaat	2400
	ctcaccact	cggtctccat	gatgctgttt	gacacccctcc	tctatgggg	gatgacccctgg	2460
	tacattgagg	ctgtctttcc	aggccgatc	ggaatttccca	ggccctgtta	ttttcttgc	2520
	accaaagtct	actggtttg	cgaggaaagt	gatgagaaga	gccaccctgg	ttccaaccag	2580
10	aagagaatat	cagaatatctg	catggaggag	gaacccaccc	acttgaagct	gggcgtgtcc	2640
	attcagaacc	tggtaaaagt	ctaccgagat	gggatgaagg	tggctgtcga	tggctggca	2700
	ctgaatttt	atgagggcca	gatcacctcc	ttcttggggc	acaatggagc	ggggaaagacg	2760
	accaccatgt	caatcctgac	cgggttgttc	cccccgaccc	cgggcaccgc	ctacatcctg	2820
	ggaaaagaca	ttcgctctga	gatgagcacc	atccggcaga	acctgggggt	ctgtccccag	2880
	cataaactgc	tgtttgcacat	gctgactgtc	gaagaacaca	tctgttctca	tgccccgttgc	2940
	aaaggggctc	ctgagaagca	cgtgaaggcg	gagatggaggc	agatggccct	ggatgttgg	3000
	ttgcccataa	gaaagctgaa	aagcaaaaca	aggccatgt	cagggttga	gcagagaaag	3060
	ctatctgtgg	ccttggcctt	tgtcggggg	tctaagggtt	tcattctgga	tgaacccaca	3120
	gctgggttgg	acccttactc	ccgcagggg	atatgggagc	tgctgctgaa	ataccgacaa	3180
	ggccgcacca	ttatttctctc	tacacaccac	atggatgaag	cggaacgttct	gggggacagg	3240
20	attgccccatca	tctccatgg	gaagctgtc	tgtgtgggt	cctccctgtt	tctgaagaac	3300
	cagctgggaa	caggctacta	cctgaccc	gtcaagaaaag	atgtggaaatc	ctccctcagt	3360
	tcctgcagaa	acagtagtag	cactgtgtc	tacctgaaaa	aggaggacag	tgttctcag	3420
	agcaggctc	atgctggcc	gggcaggcgc	catgagagtg	acacgtgtc	catcgatgtc	3480
	tctgttatct	ccaaacccat	caggaacat	gtgtcttgc	cccgctgtt	ggaagacata	3540
	gggcgttgc	tgaccttatgt	gctgcccata	gaagctgtca	aggagggac	ctttgtgg	3600
	ctcttcatg	agattgtatg	ccggcttca	gacttggca	tttcttagtt	tggcatctca	3660
	gagacgaccc	ttgaaagaaat	attcctcaag	gtggccgaag	agagtgggg	ggatgtctgag	3720
	acctcagatg	gtaccttgc	agcaagacga	aacaggccgg	ccttcgggaa	caagcagagc	3780
	tgtcttcg	cgtttactga	agatgtatgt	gctgtatccaa	atgattctga	catagaccca	3840
25	gaatccagag	agacagactt	gctcagtggg	atggatggca	aagggtctta	ccaggtgaaa	3900
	ggctgaaac	ttacacagca	acagttgtg	gcccctttgt	ggaagagact	gctaattgcc	3960
	agacggagtc	ggaaaggattt	ttttgcacat	attgttctgc	cagctgttgc	tgtctgcatt	4020
	gcccctgtgt	tccagctgt	cgtgcccacc	tttggcaagt	acccccagct	ggaacttcag	4080
	ccctggatgt	acaacgaaca	gtacacattt	gtoagcaatg	atgctctga	ggacacggga	4140
	accctggaa	tcttaaacgc	cctcacccaa	gacccctggct	tcgggaccgg	ctgtatggaa	4200
	ggaaacccaa	tcccagacac	gccctggcag	gcaggggagg	aagagtggac	cactgcccc	4260
	gttcccaga	ccatcatgga	ccttccatgg	aatgggaaact	ggacaatgca	gaacccttca	4320
30	cctgcacatg	agtgttagc	cgacaaaatc	aagaagatgc	tgcctgtgt	tcccccaggg	4380
	gcaggggggc	tgcctcttcc	acaaaagaaaa	caaaacactg	cagatattct	tcaggacctg	4440
	acaggaagaa	acatttcgga	ttatctgtg	aaagacgtatg	tgcaatgtat	agccaaaagc	4500
	ttaaaagaaca	agatctgggt	gaatgatgtt	aggatgtggcg	gctttccct	gggtgtcagt	4560
	aataactcaag	cattccttc	gagtcaagaa	gttaatgtat	ccaccaaaaca	aatgaagaaa	4620
	cacctaaagc	tggccaaagg	cagttctgc	gatcgattt	tcaacagctt	gggaagattt	4680
	atgacaggac	tggacaccag	aaataatgtc	aagggtgtgg	tcaataacaa	gggtgtccat	4740
	gcaatctat	ctttcttgc	tgtcatcaac	aatggccat	tccgggcca	cctgaaaag	4800
	ggagagaacc	ctagccatta	tggaaattact	gctttcaatc	atcccctgaa	tctcacc	4860
	cagcagctt	cagagggtgg	tccgatgacc	acatcagtgg	atgtccttgc	gtccatctgt	4920
40	gtcataatgtt	caatgtccct	cgtcccagcc	agctttgtcg	tattctgtat	ccaggagcgg	4980
	gtcagaaatg	caaaaacaccc	gcagtttcatc	agtggagtgt	agctgtat	ctactggctc	5040
	tctaattttt	tcgtggatgt	gtgcaattac	tttgcaccc	ccacactgtt	cattatc	5100
	ttcatctgt	tccagcagaa	gtccttatgt	ttctccacca	atctgcctgt	gttagccctt	5160
	ctactttgc	tgtatgggt	gtcaattaca	cctctcatgt	acccagcttc	ctttgtgttc	5220
	aagatcccc	gcacagccct	tgtgggtc	accagcgtga	accttcttcat	tggcattaaat	5280
	ggcagcgtgg	ccaccccttgc	gctggagctg	tttacccgaca	ataagctgaa	taatatcaat	5340
	gatattctga	agtccgttgc	tttgatctt	ccacat	gcctgggac	agggtctatc	5400
	gacatggta	aaaaccaggc	aatggctgtat	gcccctggaa	ggtttgggaa	gaatcgcttt	5460
	gtgtcaccat	tatcttggga	cttgggtgg	cgaaacccct	tcggccatgc	cgtgaaaggg	5520
	gtgggttct	tcctcatttt	tgttctgtat	cagtagatgt	tcttcatc	gcccagaccc	5580
	gtaaatgca	agctatcttc	tctgaatgtat	gaatgtatgt	atgtgaggcg	ggaaagacag	5640
	agaattctt	atggtggagg	ccagaatgtac	atcttagaaa	tcaaggatgt	gacaaagata	5700
55	tatagaagga	agcggaaagcc	tgctgttgac	aggatttgcg	ttggcattcc	tccttgcgtag	5760
	tgcttgggc	tcctgggatgt	taatggggct	ggaaaatcat	caacttca	gatgttaaca	5820

5 ggagatacca ctgttaccag aggagatgct ttccttaaca gaaatagttat cttatcaaac 5880  
 atccatgaag tacatcagaa catggctac tgccctcagt ttgatccat cacagagctg 5940  
 ttgactggga gagaacacgt ggagtcttt gccctttga gaggagtccc agagaaagaa 6000  
 gttggcaagg ttggtaggtt ggcgttccgg aaactggcc tcgtgaagta tggagaaaa 6060  
 tatgtggta actatagtgg aggcaacaaa cgcaagctc ctacaggcat ggcttgatc 6120  
 ggcggccctc ctgtgggtt tctggatgaa cccaccacag gcatggatcc caaagccccg 6180  
 cggttcttgtt ggaattgtgc cctaaatgtt gtcaaggagg ggagatcagt agtgcttaca 6240  
 tctcatagta tggagaatg tgaagcttt tgcaacttagga tggcaatcat ggtcaatgga 6300  
 aggttcagggt gccttggcag tgcaggcat ctaaaaaata gggttggaga tggttataaca 6360  
 10 atagttgtac gaatagcagg gtccaaacccg gacctgaagc ctgtccagga tttctttgga 6420  
 ctgcatttc ctggaagttt tccaaaagag aaacacccgga acatgttaca ataccagtt 6480  
 ccatcttcat tatcttctt ggccaggata ttccatcc tctccagag caaaaagcga 6540  
 cccacatag aagactactc tgtttctcag acaacactt accaagtatt tgtgaacttt 6600  
 gccaaggaggc aaagtgtata tgaccactta aaagactt cattacacaa aaaccagaca 6660  
 gtagtgacg ttgcagttt cccatcttt ctacaggatg agaaagtgaa agaaagcttat 6720  
 gtatgaagaa tccctgttcat acgggggtggc tgaaagttaa gagggactag actttccctt 6780  
 15 gcaccatgtg aagtgttgcg gagaaagag ccagaagttt atgtggaaag aagtaaactg 6840  
 gatactgtac tgatactatt caatgcaatg caattcaatg 6880

20 <210> 2  
 <211> 2201  
 <212> PRT  
 <213> Human

25 <220>  
 <223> Peptide sequence of ABCA1 (ABCA1)

30 <400> 2  
 Met Pro Ser Ala Gly Thr Leu Pro Trp Val Gln Gly Ile Ile Cys Asn  
 1 5 10 15

Ala Asn Asn Pro Cys Phe Arg Tyr Pro Thr Pro Gly Glu Ala Pro Gly  
 20 25 30

35 Val Val Gly Asn Phe Asn Lys Ser Ile Val Ala Arg Leu Phe Ser Asp  
 35 40 45

40 Ala Arg Arg Leu Leu Tyr Ser Gln Lys Asp Thr Ser Met Lys Asp  
 50 55 60

Met Arg Lys Val Leu Arg Thr Leu Gln Gln Ile Lys Lys Ser Ser Ser  
 65 70 75 80

45 Asn Leu Lys Leu Gln Asp Phe Leu Val Asp Asn Glu Thr Phe Ser Gly  
 85 90 95

Phe Leu Tyr His Asn Leu Ser Leu Pro Lys Ser Thr Val Asp Lys Met  
 100 105 110

50 Leu Arg Ala Asp Val Ile Leu His Lys Val Phe Leu Gln Gly Tyr Gln  
 115 120 125

Leu His Leu Thr Ser Leu Cys Asn Gly Ser Lys Ser Glu Glu Met Ile  
 130 135 140

55 Gln Leu Gly Asp Gln Glu Val Ser Glu Leu Cys Gly Leu Pro Arg Glu  
 145 150 155 160

Lys Leu Ala Ala Ala Glu Arg Val Leu Arg Ser Asn Met Asp Ile Leu  
 165 170 175

Lys Pro Ile Leu Arg Thr Leu Asn Ser Thr Ser Pro Phe Pro Ser Lys  
 180 185 190

## EP 1 136 552 A1

Glu Leu Ala Glu Ala Thr Lys Thr Leu Leu His Ser Leu Gly Thr Leu  
 195 200 205  
 5 Ala Gln Glu Leu Phe Ser Met Arg Ser Trp Ser Asp Met Arg Gln Glu  
 210 215 220  
 Val Met Phe Leu Thr Asn Val Asn Ser Ser Ser Ser Thr Gln Ile  
 225 230 235 240  
 10 Tyr Gln Ala Val Ser Arg Ile Val Cys Gly His Pro Glu Gly Gly  
 245 250 255  
 Leu Lys Ile Lys Ser Leu Asn Trp Tyr Glu Asp Asn Asn Tyr Lys Ala  
 260 265 270  
 15 Leu Phe Gly Gly Asn Gly Thr Glu Glu Asp Ala Glu Thr Phe Tyr Asp  
 275 280 285  
 Asn Ser Thr Thr Pro Tyr Cys Asn Asp Leu Met Lys Asn Leu Glu Ser  
 290 295 300  
 20 Ser Pro Leu Ser Arg Ile Ile Trp Lys Ala Leu Lys Pro Leu Leu Val  
 305 310 315 320  
 Gly Lys Ile Leu Tyr Thr Pro Asp Thr Pro Ala Thr Arg Gln Val Met  
 325 330 335  
 25 Ala Glu Val Asn Lys Thr Phe Gln Glu Leu Ala Val Phe His Asp Leu  
 340 345 350  
 Glu Gly Met Trp Glu Glu Leu Ser Pro Lys Ile Trp Thr Phe Met Glu  
 355 360 365  
 30 Asn Ser Gln Glu Met Asp Leu Val Arg Met Leu Leu Asp Ser Arg Asp  
 370 375 380  
 Asn Asp His Phe Trp Glu Gln Gln Leu Asp Gly Leu Asp Trp Thr Ala  
 385 390 395 400  
 35 Gln Asp Ile Val Ala Phe Leu Ala Lys His Pro Glu Asp Val Gln Ser  
 405 410 415  
 Ser Asn Gly Ser Val Tyr Thr Trp Arg Glu Ala Phe Asn Glu Thr Asn  
 420 425 430  
 40 Gln Ala Ile Arg Thr Ile Ser Arg Phe Met Glu Cys Val Asn Leu Asn  
 435 440 445  
 Lys Leu Glu Pro Ile Ala Thr Glu Val Trp Leu Ile Asn Lys Ser Met  
 450 455 460  
 Glu Leu Leu Asp Glu Arg Lys Phe Trp Ala Gly Ile Val Phe Thr Gly  
 465 470 475 480  
 Ile Thr Pro Gly Ser Ile Glu Leu Pro His His Val Lys Tyr Lys Ile  
 485 490 495  
 Arg Met Asp Ile Asp Asn Val Glu Arg Thr Asn Lys Ile Lys Asp Gly  
 500 505 510  
 55 Tyr Trp Asp Pro Gly Pro Arg Ala Asp Pro Phe Glu Asp Met Arg Tyr  
 515 520 525

## EP 1 136 552 A1

Val Trp Gly Gly Phe Ala Tyr Leu Gln Asp Val Val Glu Gln Ala Ile  
 530 535 540  
 5 Ile Arg Val Leu Thr Gly Thr Glu Lys Lys Thr Gly Val Tyr Met Gln  
 545 550 555 560  
 Gln Met Pro Tyr Pro Cys Tyr Val Asp Asp Ile Phe Leu Arg Val Met  
 565 570 575  
 10 Ser Arg Ser Met Pro Leu Phe Met Thr Leu Ala Trp Ile Tyr Ser Val  
 580 585 590  
 Ala Val Ile Ile Lys Gly Ile Val Tyr Glu Lys Glu Ala Arg Leu Lys  
 595 600 605  
 15 Glu Thr Met Arg Ile Met Gly Leu Asp Asn Ser Ile Leu Trp Phe Ser  
 610 615 620  
 Trp Phe Ile Ser Ser Leu Ile Pro Leu Leu Val Ser Ala Gly Leu Leu  
 625 630 635 640  
 20 Val Val Ile Leu Lys Leu Gly Asn Leu Leu Pro Tyr Ser Asp Pro Ser  
 645 650 655  
 Val Val Phe Val Phe Leu Ser Val Phe Ala Val Val Thr Ile Leu Gln  
 660 665 670  
 25 Cys Phe Leu Ile Ser Thr Leu Phe Ser Arg Ala Asn Leu Ala Ala Ala  
 675 680 685  
 Cys Gly Gly Ile Ile Tyr Phe Thr Leu Tyr Leu Pro Tyr Val Leu Cys  
 690 695 700  
 30 Val Ala Trp Gln Asp Tyr Val Gly Phe Thr Leu Lys Ile Phe Ala Ser  
 705 710 715 720  
 Leu Leu Ser Pro Val Ala Phe Gly Phe Gly Cys Glu Tyr Phe Ala Leu  
 35 725 730 735  
 Phe Glu Glu Gln Gly Ile Gly Val Gln Trp Asp Asn Leu Phe Glu Ser  
 740 745 750  
 Pro Val Glu Glu Asp Gly Phe Asn Leu Thr Thr Ser Val Ser Met Met  
 40 755 760 765  
 Leu Phe Asp Thr Phe Leu Tyr Gly Val Met Thr Trp Tyr Ile Glu Ala  
 770 775 780  
 45 Val Phe Pro Gly Gln Tyr Gly Ile Pro Arg Pro Trp Tyr Phe Pro Cys  
 785 790 795 800  
 Thr Lys Ser Tyr Trp Phe Gly Glu Glu Ser Asp Glu Lys Ser His Pro  
 805 810 815  
 50 Gly Ser Asn Gln Lys Arg Ile Ser Glu Ile Cys Met Glu Glu Pro  
 820 825 830  
 Thr His Leu Lys Leu Gly Val Ser Ile Gln Asn Leu Val Lys Val Tyr  
 835 840 845  
 55 Arg Asp Gly Met Lys Val Ala Val Asp Gly Leu Ala Leu Asn Phe Tyr  
 850 855 860

## EP 1 136 552 A1

Glu Gly Gln Ile Thr Ser Phe Leu Gly His Asn Gly Ala Gly Lys Thr  
 865 870 875 880  
 5 Thr Thr Met Ser Ile Leu Thr Gly Leu Phe Pro Pro Thr Ser Gly Thr  
 885 890 895  
 Ala Tyr Ile Leu Gly Lys Asp Ile Arg Ser Glu Met Ser Thr Ile Arg  
 900 905 910  
 10 Gln Asn Leu Gly Val Cys Pro Gln His Asn Val Leu Phe Asp Met Leu  
 915 920 925  
 Thr Val Glu Glu His Ile Trp Phe Tyr Ala Arg Leu Lys Gly Leu Ser  
 930 935 940  
 15 Glu Lys His Val Lys Ala Glu Met Glu Gln Met Ala Leu Asp Val Gly  
 945 950 955 960  
 Leu Pro Ser Ser Lys Leu Lys Ser Lys Thr Ser Gln Leu Ser Gly Gly  
 965 970 975  
 20 Met Gln Arg Lys Leu Ser Val Ala Leu Ala Phe Val Gly Gly Ser Lys  
 980 985 990  
 Val Val Ile Leu Asp Glu Pro Thr Ala Gly Val Asp Pro Tyr Ser Arg  
 995 1000 1005  
 25 Arg Gly Ile Trp Glu Leu Leu Lys Tyr Arg Gln Gly Arg Thr Ile  
 1010 1015 1020  
 Ile Leu Ser Thr His His Met Asp Glu Ala Asp Val Leu Gly Asp Arg  
 1025 1030 1035 1040  
 30 Ile Ala Ile Ile Ser His Gly Lys Leu Cys Cys Val Gly Ser Ser Leu  
 1045 1050 1055  
 Phe Leu Lys Asn Gln Leu Gly Thr Gly Tyr Tyr Leu Thr Leu Val Lys  
 1060 1065 1070  
 35 Lys Asp Val Glu Ser Ser Leu Ser Ser Cys Arg Asn Ser Ser Thr  
 1075 1080 1085  
 Val Ser Tyr Leu Lys Glu Asp Ser Val Ser Gln Ser Ser Ser Asp  
 1090 1095 1100  
 40 Ala Gly Leu Gly Ser Asp His Glu Ser Asp Thr Leu Thr Ile Asp Val  
 1105 1110 1115 1120  
 Ser Ala Ile Ser Asn Leu Ile Arg Lys His Val Ser Glu Ala Arg Leu  
 1125 1130 1135  
 Val Glu Asp Ile Gly His Glu Leu Thr Tyr Val Leu Pro Tyr Glu Ala  
 1140 1145 1150  
 45 Ala Lys Glu Gly Ala Phe Val Glu Leu Phe His Glu Ile Asp Asp Arg  
 1155 1160 1165  
 Leu Ser Asp Leu Gly Ile Ser Ser Tyr Gly Ile Ser Glu Thr Thr Leu  
 1170 1175 1180  
 50 Glu Glu Ile Phe Leu Lys Val Ala Glu Glu Ser Gly Val Asp Ala Glu  
 1185 1190 1195 1200

## EP 1 136 552 A1

Thr Ser Asp Gly Thr Leu Pro Ala Arg Arg Asn Arg Arg Ala Phe Gly  
 1205 1210 1215  
 5 Asp Lys Gln Ser Cys Leu Arg Pro Phe Thr Glu Asp Asp Ala Ala Asp  
 1220 1225 1230  
 Pro Asn Asp Ser Asp Ile Asp Pro Glu Ser Arg Glu Thr Asp Leu Leu  
 1235 1240 1245  
 10 Ser Gly Met Asp Gly Lys Gly Ser Tyr Gln Val Lys Gly Trp Lys Leu  
 1250 1255 1260  
 Thr Gln Gln Gln Phe Val Ala Leu Leu Trp Lys Arg Leu Leu Ile Ala  
 1265 1270 1275 1280  
 15 Arg Arg Ser Arg Lys Gly Phe Phe Ala Gln Ile Val Leu Pro Ala Val  
 1285 1290 1295  
 Phe Val Cys Ile Ala Leu Val Phe Ser Leu Ile Val Pro Pro Phe Gly  
 1300 1305 1310  
 20 Lys Tyr Pro Ser Leu Glu Leu Gln Pro Trp Met Tyr Asn Glu Gln Tyr  
 1315 1320 1325  
 Thr Phe Val Ser Asn Asp Ala Pro Glu Asp Thr Gly Thr Leu Glu Leu  
 1330 1335 1340  
 25 Leu Asn Ala Leu Thr Lys Asp Pro Gly Phe Gly Thr Arg Cys Met Glu  
 1345 1350 1355 1360  
 Gly Asn Pro Ile Pro Asp Thr Pro Cys Gln Ala Gly Glu Glu Trp  
 1365 1370 1375  
 30 Thr Thr Ala Pro Val Pro Gln Thr Ile Met Asp Leu Phe Gln Asn Gly  
 1380 1385 1390  
 Asn Trp Thr Met Gln Asn Pro Ser Pro Ala Cys Gln Cys Ser Ser Asp  
 35 1395 1400 1405  
 Lys Ile Lys Lys Met Leu Pro Val Cys Pro Pro Gly Ala Gly Gly Leu  
 1410 1415 1420  
 Pro Pro Pro Gln Arg Lys Gln Asn Thr Ala Asp Ile Leu Gln Asp Leu  
 40 1425 1430 1435 1440  
 Thr Gly Arg Asn Ile Ser Asp Tyr Leu Val Lys Thr Tyr Val Gln Ile  
 1445 1450 1455  
 Ile Ala Lys Ser Leu Lys Asn Lys Ile Trp Val Asn Glu Phe Arg Tyr  
 45 1460 1465 1470  
 Gly Gly Phe Ser Leu Gly Val Ser Asn Thr Gln Ala Leu Pro Pro Ser  
 1475 1480 1485  
 Gln Glu Val Asn Asp Ala Thr Lys Gln Met Lys Lys His Leu Lys Leu  
 50 1490 1495 1500  
 Ala Lys Asp Ser Ser Ala Asp Arg Phe Leu Asn Ser Leu Gly Arg Phe  
 1505 1510 1515 1520  
 Met Thr Gly Leu Asp Thr Arg Asn Asn Val Lys Val Trp Phe Asn Asn  
 55 1525 1530 1535

## EP 1 136 552 A1

Lys Gly Trp His Ala Ile Ser Ser Phe Leu Asn Val Ile Asn Asn Ala  
 1540 1545 1550  
 5 Ile Leu Arg Ala Asn Leu Gln Lys Gly Glu Asn Pro Ser His Tyr Gly  
 1555 1560 1565  
 Ile Thr Ala Phe Asn His Pro Leu Asn Leu Thr Lys Gln Gln Leu Ser  
 1570 1575 1580  
 10 Glu Val Ala Pro Met Thr Thr Ser Val Asp Val Leu Val Ser Ile Cys  
 1585 1590 1595 1600  
 Val Ile Phe Ala Met Ser Phe Val Pro Ala Ser Phe Val Val Phe Leu  
 1605 1610 1615  
 15 Ile Gln Glu Arg Val Ser Lys Ala Lys His Leu Gln Phe Ile Ser Gly  
 1620 1625 1630  
 Val Lys Pro Val Ile Tyr Trp Leu Ser Asn Phe Val Trp Asp Met Cys  
 1635 1640 1645  
 20 Asn Tyr Val Val Pro Ala Thr Leu Val Ile Ile Ile Phe Ile Cys Phe  
 1650 1655 1660  
 Gln Gln Lys Ser Tyr Val Ser Ser Thr Asn Leu Pro Val Leu Ala Leu  
 1665 1670 1675 1680  
 25 Leu Leu Leu Leu Tyr Trp Ser Ile Thr Pro Leu Met Tyr Pro Ala  
 1685 1690 1695  
 Ser Phe Val Phe Lys Ile Pro Ser Thr Ala Tyr Val Val Leu Thr Ser  
 1700 1705 1710  
 30 Val Asn Leu Phe Ile Gly Ile Asn Gly Ser Val Ala Thr Phe Val Leu  
 1715 1720 1725  
 Glu Leu Phe Thr Asp Asn Lys Leu Asn Asn Ile Asn Asp Ile Leu Lys  
 1730 1735 1740  
 35 Ser Val Phe Leu Ile Phe Pro His Phe Cys Leu Gly Arg Gly Leu Ile  
 1745 1750 1755 1760  
 Asp Met Val Lys Asn Gln Ala Met Ala Asp Ala Leu Glu Arg Phe Gly  
 40 1765 1770 1775  
 Glu Asn Arg Phe Val Ser Pro Leu Ser Trp Asp Leu Val Gly Arg Asn  
 1780 1785 1790  
 45 Leu Phe Ala Met Ala Val Glu Gly Val Val Phe Phe Leu Ile Thr Val  
 1795 1800 1805  
 Leu Ile Gln Tyr Arg Phe Phe Ile Arg Pro Arg Pro Val Asn Ala Lys  
 1810 1815 1820  
 50 Leu Ser Pro Leu Asn Asp Glu Asp Glu Asp Val Arg Arg Glu Arg Gln  
 1825 1830 1835 1840  
 Arg Ile Leu Asp Gly Gly Gln Asn Asp Ile Leu Glu Ile Lys Glu  
 1845 1850 1855  
 55 Leu Thr Lys Ile Tyr Arg Arg Lys Arg Lys Pro Ala Val Asp Arg Ile  
 1860 1865 1870

Cys Val Gly Ile Pro Pro Gly Glu Cys Phe Gly Leu Leu Gly Val Asn  
 1875 1880 1885  
 5 Gly Ala Gly Lys Ser Ser Thr Phe Lys Met Leu Thr Gly Asp Thr Thr  
 1890 1895 1900  
 Val Thr Arg Gly Asp Ala Phe Leu Asn Arg Asn Ser Ile Leu Ser Asn  
 1905 1910 1915 1920  
 10 Ile His Glu Val His Gln Asn Met Gly Tyr Cys Pro Gln Phe Asp Ala  
 1925 1930 1935  
 Ile Thr Glu Leu Leu Thr Gly Arg Glu His Val Glu Phe Phe Ala Leu  
 1940 1945 1950  
 15 Leu Arg Gly Val Pro Glu Lys Glu Val Gly Lys Val Gly Glu Trp Ala  
 1955 1960 1965  
 Ile Arg Lys Leu Gly Leu Val Lys Tyr Gly Glu Lys Tyr Ala Gly Asn  
 1970 1975 1980  
 20 Tyr Ser Gly Gly Asn Lys Arg Lys Leu Ser Thr Ala Met Ala Leu Ile  
 1985 1990 1995 2000  
 Gly Gly Pro Pro Val Val Phe Leu Asp Glu Pro Thr Thr Gly Met Asp  
 2005 2010 2015  
 25 Pro Lys Ala Arg Arg Phe Leu Trp Asn Cys Ala Leu Ser Val Val Lys  
 2020 2025 2030  
 Glu Gly Arg Ser Val Val Leu Thr Ser His Ser Met Glu Glu Cys Glu  
 2035 2040 2045  
 30 Ala Leu Cys Thr Arg Met Ala Ile Met Val Asn Gly Arg Phe Arg Cys  
 2050 2055 2060  
 Leu Gly Ser Val Gln His Leu Lys Asn Arg Phe Gly Asp Gly Tyr Thr  
 2065 2070 2075 2080  
 35 Ile Val Val Arg Ile Ala Gly Ser Asn Pro Asp Leu Lys Pro Val Gln  
 2085 2090 2095  
 Asp Phe Phe Gly Leu Ala Phe Pro Gly Ser Val Pro Lys Glu Lys His  
 2100 2105 2110  
 40 Arg Asn Met Leu Gln Tyr Gln Leu Pro Ser Ser Leu Ser Ser Leu Ala  
 2115 2120 2125  
 Arg Ile Phe Ser Ile Leu Ser Gln Ser Lys Lys Arg Leu His Ile Glu  
 2130 2135 2140  
 45 Asp Tyr Ser Val Ser Gln Thr Thr Leu Asp Gln Val Phe Val Asn Phe  
 2145 2150 2155 2160  
 Ala Lys Asp Gln Ser Asp Asp His Leu Lys Asp Leu Ser Leu His  
 2165 2170 2175  
 Lys Asn Gln Thr Val Val Asp Val Ala Val Leu Thr Ser Phe Leu Gln  
 2180 2185 2190  
 50 Asp Glu Lys Val Lys Glu Ser Tyr Val  
 2195 2200

**Claims**

1. A polynucleotide comprising a member selected from the group consisting of:
  - 5 (a) a polynucleotide as set forth in SEQ ID NO:1 with the sequence variants G596A or T1136C or A2589G or G3456C or any combination of these variants;
  - (b) a polynucleotide fragment of the polynucleotides of (a) containing the variants G596A or T1136C or A2589G or G3456C or any combination of these variants.
- 10 2. The polynucleotide of claim 1 wherein the polynucleotide is DNA.
3. A vector containing one or more of the polynucleotides of claim 1 and 2.
- 15 4. A host cell containing the vector of claim 3.
5. A process for producing a polypeptide comprising: expressing from the host cell of claim 4 the polypeptide encoded by said DNA.
- 20 6. An assay using one of the materials of claims 1 to 4 for the detection of the ABC1 gene transcripts.
7. An assay using one of the materials of claims 1 to 4 for the detection of the ABC1 variants G596A or T1136C or A2589G or G3456C.
- 25 8. A polypeptide selected from the group consisting of:
  - a) a polypeptide having the deduced amino acid sequence of SEQ ID NO:1 and
  - 30 b) fragments, analogs and derivatives thereof containing the sequence variants of claim 2b.
9. An antibody capable to bind to the polypeptide of claim 8.
10. An assay using one of the materials of claims 8 and 9 for the detection of:
  - 35 (a) the ABC1 protein or fragments, analogs and derivatives thereof,
  - (b) the deduced protein or fragments, analogs and derivatives thereof from the ABC1 sequence variants G596A or T1136C or A2589G or G3456C .
- 40 11. A diagnostic kit for the detection of the ABC1 gene variants G596A or T1136C or A2589G or G3456C.
12. Modulator of polypeptides encoded by a polynucleotide comprising a member selected from the group consisting of:
  - 45 (a) a polynucleotide as set forth in SEQ ID NO:1 and
  - (b) a polynucleotide fragment of the polynucleotide of (a) containing the sequence variants G596A or T1136C or A2589G or G3456C.
13. A pharmaceutical comprising the modulator of claim 12.
- 50 14. The modulation of ABC1 transcripts or proteins or fragments thereof by gene therapy.
15. The modulation of ABC1 transcripts or proteins or fragments thereof by antisense or ribozyme technology or RNA decoys.

Figure 1: cDNA of human ABC1 gene

```

1  AAACCCCGTA ATTGCGAGCG AGAGTGAGTG GGGCCGGGAC CCGCAGAGCC
51  GAGCCGACCC TTCTCTCCCG GGCTCGGGCA GGGCAGGGCG GGGAGCTCCG
101  CGCACCAACA GAGCCGGTTC TCAGGGCGCT TTGCTCCTTG TTTTTTCCCC
151  GGTTCTGTT TCTCCCTTC TCCGGAAGGC TTGTCAAGGG GTAGGAGAAA
201  GAGACGCAAA CACAAAAGTG GAAAACAGTT AATGACCAGC CACGGCGTCC
251  CTGCTGTGAG CTCTGGCGC TGCCCTCCAG GGCTCCGAG CCACACCGCTG
301  GGGGTGCTGG CTGAGGGAAAC ATGGCTTGTG GGCCTCAGCT GAGGTIGCTG
351  CTGTGGAAAGA ACCTCACTTT CAGAAGAAGA caaacatgtc agctgttact
401  ggaagtggcc tggcctctat ttatcttctt gatcctgtatc tctgttccggc
451  tgagctaccc accatcatgaa caacatgaat gccattttcc aaataaaagcc
501  atgcccctcg caggaacact tccttgggtt caggggatata tctgtatgc
551  caacaacccc tggttccgtt acccgactcc tggggaggct cccggagttg
601  ttggaaactt taacaaatcc attgtggctc ggctgttctc agatgtctgg
651  aggcttctt tatacagcca gaaagacacc agcatgaagg acatgogcaa
701  agttctgaga acattacagc agatcaagaa atccagctca aacttgaagc
751  ttcaagattt cctgggtggac aatgaaacct tctctgggtt cctgtatcac
801  aacctctctc tcccaaagtcc tactgtggac aagatgtctga gggctgtatgt
851  cattctccac aaggatatttt tgcaaggctt ccagttacat ttgacaagtc
901  tggcaatgg atcaaaaatca gaagagatga ttcaacttgg tgaccaagaa
951  gtttctgagc ttttgggtt accaaggggaa aacttggctg cagcagagcg
1001 agtacttcgt tccaaacatgg acatcctgaa gccaatcctg agaacactaa
1051 actctacatc tcccttcccg agcaaggagc tggccgaagc cacaaaaaaca
1101 ttgctgcata gtcttggac tcttggccag gagctgttca gcatgagaag
1151 ctggagtggc atggcagcagg aggtgtatgtt tctgaccaat gtgaacagct
1201 ccagctctc cacccaaate taccaggctg tgcgttctat tgcgtcgccc
1251 catcccgagg gaggggggctt gaagatcaag tctctcaact ggtatgagga
1301 caacaactaa aagccctct ttggaggccaa tggcaactgag gaagatgctg
1351 aaaccttcta tgacaactct acaactccctt actgcaatga tttgtatgaag
1401 aatttggagt ctatcctct ttcccgatt atctggaaag ctctgaagcc
1451 gctgctcggtt ggaaagatcc tgcgttacacc tgacactcca gcccacaaggc
1501 aggtcatggc tgagggttggac aagacccccc aggaactggc tgggttccat
1551 gatctggaaag gcatgtggga ggaactcage cccaaatctt ggcacccat
1601 ggagaacacgca caaaggatgg accttggcc gatgtgttgc gacagcagg
1651 acaatgacca ctttggggaa cagcagtttgg atggcttgc ttggacagcc
1701 caagacatcg tggcggtttt ggccaagcac ccagaggatg tccagtccag
1751 taatggttct gtgtacaccc ggagagaagc ttcaacccgg actaaccagg
1801 caatccggac catatctcgc ttcatggagt gtgtcaaccc gaacaagctt
1851 gaacccttag caacagaatgt ctggctcat aacaatccca tggagctgtc
1901 ggatgagagg aagtcttggg ctggatattgtt gttcaactggg attactccag
1951 gcacgttgc gctggcccat catgtcaagt acaagatccg aatggacatt
2001 gacaatgtgg agaggacaaa taaaatcaag gatgggtact gggaccctgg
2051 tcctcgagct gacccttttgg aggacatgcg gtacgtctgg gggggcttgc
2101 cctacttgc ggtatgtggc gaggcaggccaa tcatacagggt gctgacggcc
2151 accgagaaga aaacttgggtt ctatatgcaaa cagatccctt atccctgtta
2201 cgttgcgttgc atcttctgc ggggtgttgc cccgtcaatg ccccttccat
2251 tgacgttgc ctggatttac tcagttggctg tgatcatcaa gggcatcggt
2301 tatgagaagg aggacacggct gaaagagacc atgcggatca tggggcttgg
2351 caacagcata ctctggtttca gctggatccat tagtagccctc attcccttcc
2401 ttgtgagcgc tggcctgtca gtggatccatcc tgaagtttagg aacactgtct
2451 ccctacagtg atccccagcgt ggtgtttgtc ttccctgtccg tgggttgcgt
2501 ggtgacatac ctgcgtgtc tcctgtttagt cacacttcc tccagagccca
2551 accttggcaggc agccctgtggg ggcacatcatc acttcacgct gtacgtcccc
2601 tacgttccgtt gtgttgcgttgc gaggactac gtggccttca cactcaagat
2651 cttcgttgcgttgc ctgttgcgttgc tgggtttggc tgggttgcgt
2701 ttggcccttt tgaggagcag ggcattggag tggcgttgc tgggttgcgt
2751 gagagtccgt tggaggaaaga tggcttcaat ctcaccactt cgggttccat
2801 gatgtgtttt gacacccccc tctatgggtt gatgacccctgg tacatttgg
2851 ctgttccgttcc agggcaggatc gggatccca gggccctggta ttttccgttgc
2901 accaagtccct actgggtttgg cggaggaaatgt gatgagaaga gcccaccctgg
2951 ttccaaccatc aagagaatat cagaaatctg catggaggag gaaaccacc
3001 acttgaagct gggcgtgtcc attcagaacc tggtaaaatgtt ctaccgagat
3051 gggatgaaagg tggctgtcga tggcctggca ctgaattttt atgaggggcca
3101 gatcacccatcc ttccctggcc acaatggagc ggggaagacg accaccatgt

```

3151 caatcctgac cgggttgttc ccccccacct cgggcaccgc ctacatcctg  
 3201 ggaaaagaca ttgcgtctga gatgagcacc atccggcaga acctgggggt  
 3251 ctgtccccag cataaacgtgc tggttgacat gctgactgtc gaagaacaca  
 3301 tctgggtcta tgcccgctt aaagggtctt ctgagaagca cgtgaaggcg  
 3351 gagatggagc agatggccct ggatgttgc ttgcacatcaa gcaagctgaa  
 3401 aagcaaaca aaccagctgt cagggttgc tctaagggtt tcattcttgc tgaacccaca  
 3451 ccttggcctt tgcgggggaa atatgggagc tgctgctgaa  
 3501 gctgggtgtt acccttactc ccgcaggggaa tacacaccac atggatgaa  
 3551 ataccgacaa gccgcacca ttattcttgc tacacaccac atggatgaa  
 3601 cggacgtctt gggggcaggc attggccatca tctccatgg gaagctgtgc  
 3651 tgggtgggtt cctccctgtt tctgaagaac cagctggaa caggctacta  
 3701 cctgacccctt gtcaagaaag atgttgcattt ctccttcattt tcctgcagaa  
 3751 acagtagtag cactgtgtca tacctgaaaaa aggaggacag tggttcttag  
 3801 agcagttctt atgttgcattt gggcagcgc catgagagtg acacgctgac  
 3851 catcgatgtc tctgttatctt ccaacccatc caggaagcat gtgtctgaa  
 3901 cccggctgtt ggaagacata gggcatgagc tgaccatgt gctgcccatt  
 3951 gaagctgtt aaggaggagc ctttggggaa ctcttcattt agattgtgaa  
 4001 cccgcttcata gacccggca ttcttgcattt tggcatctca gagacgaccc  
 4051 tggaaagaaat attcctcaag tggggccggag agatgtgggtt ggatgtgag  
 4101 acctcagatg gtacccgttcc gcaagacgc aacaggcgcc ctttcggggaa  
 4151 caagcagagc tgcgtttccgc cgttcaactg agatgtgtc gctgatccaa  
 4201 atgattcttgc catagacccca gaatccagag agacagactt gtcagtgaa  
 4251 atggatggca aagggtccca ccagggtggaa ggctggaaac ttacacagca  
 4301 acagtttgc gcccctttgtt ggaagagact gctaatttgc agacggagtc  
 4351 gggaaaggatt ttttgcatttgc ctttgcatttgc ctttgcatttgc ttttgcatttgc  
 4401 gcccctgtgt tcagcctgtt ctttgcatttgc ctttgcatttgc acccacggct  
 4451 ggaacttcag ccctggatgtt acaacgaaca gtacacattt gtcagcaatg  
 4501 atgcttcata ggcacacggga acccttggaa tcttaaacgc ctcaccaaa  
 4551 gaccctggct tcgggaccgg aatggccatca gggccatca tcccaacac  
 4601 gcccctgcctt gcaaggggagg aatggccatca gggccatca tcccaacac  
 4651 cccatcatggc cctttccatc aatggccatca gggccatca tcccaacac  
 4701 cctgcatttgc agtttgcatttgc ctttgcatttgc ttttgcatttgc  
 4751 tccccccatggc gcaaggggggc aatggccatca gggccatca tcccaacac  
 4801 cagatattttgc tcaggacccgc aatggccatca gggccatca tcccaacac  
 4851 aagacgtatg tgcagatcat aatggccatca gggccatca tcccaacac  
 4901 gaatggatgtt agtttgcatttgc aatggccatca gggccatca tcccaacac  
 4951 cacttcatttgc gaggcaaaaaa aatggccatca gggccatca tcccaacac  
 5001 cacattaaatgc tggccaaaggc aatggccatca gggccatca tcccaacac  
 5051 gggaaaggattt atgacaggac tggccaaaggc aatggccatca gggccatca tcccaacac  
 5101 tcaataacaa gggctggcat gcaatcatttgc aatggccatca gggccatca tcccaacac  
 5151 aatggccatcc tccggggccaa ctttgcatttgc aatggccatca gggccatca tcccaacac  
 5201 tggaaattact gcttcataatc atcccttgcatttgc aatggccatca gggccatca tcccaacac  
 5251 cagagggtggc tccgttgcatttgc aatggccatca gggccatca tcccaacac  
 5301 gtcatctttgc caatgttgcatttgc aatggccatca gggccatca tcccaacac  
 5351 ccaggaggcg gtcatttgcatttgc aatggccatca gggccatca tcccaacac  
 5401 agcctgtcat ctactggctt aatggccatca gggccatca tcccaacac  
 5451 gttgtcccttgc ccacacttgcatttgc aatggccatca gggccatca tcccaacac  
 5501 gtcctatgtt tcctccatca aatggccatca gggccatca tcccaacac  
 5551 tggatgggtt gtcatttgcatttgc aatggccatca gggccatca tcccaacac  
 5601 aagatccccca gcacaggctt gtcatttgcatttgc aatggccatca gggccatca tcccaacac  
 5651 tggcattaaatgc ggcacgtttgcatttgc aatggccatca gggccatca tcccaacac  
 5701 ataagcttgcatttgc aatggccatca gggccatca tcccaacac  
 5751 ccacattttgc gcttggggacgc aatggccatca gggccatca tcccaacac  
 5801 aatggctgtt gcccctggaaa aatggccatca gggccatca tcccaacac  
 5851 tatcttgggtt ctgggtgggtt gtcatttgcatttgc aatggccatca gggccatca tcccaacac  
 5901 gtgggttttgc ttcttcatttgc aatggccatca gggccatca tcccaacac  
 5951 gcccaggacccgc gtaatgcatttgc aatggccatca gggccatca tcccaacac  
 6001 atgttggggc gggaaaggacag aatggccatca gggccatca tcccaacac  
 6051 atctttagaaatgc tcaaggatgttgc aatggccatca gggccatca tcccaacac  
 6101 tgctgttgcatttgc aatggccatca gggccatca tcccaacac  
 6151 tcctggggatgttgcatttgc aatggccatca gggccatca tcccaacac  
 6201 ggagataccatc ctgttaccatc aatggccatca gggccatca tcccaacac  
 6251 cttatcaacatccatc aatggccatca gggccatca tcccaacac  
 6301 ttgtatgcatttgc aacaggatgttgcatttgc aatggccatca gggccatca tcccaacac  
 6351 gccccttgcatttgc aatggccatca gggccatca tcccaacac  
 6401 ggcgatttgcatttgc aatggccatca gggccatca tcccaacac

```

6451 actatagtgg aggcaacaaa cgcaagctct ctacagccat ggctttgatc
6501 ggcgggcctc ctgtgggtt tctggatgaa cccaccacag gcatggatcc
6551 caaagccccg cggttcttgt ggaattgtgc cctaagtgtt gtcaggagg
6601 ggagatca gatgtttaca tctcatagta tggaaataatg tgaagcttt
6651 tgcacttagg tggcaatcat gtcataatggg aggttcagg gccttggcag
6701 tgtccagat ctaaaaaata gttttggaga tggttataca atagttgtac
6751 gaatagcagg gtccaaacccg gacctaaggc ctgtccaggaa ttctttgg
6801 cttgcatttc ctggaaatgtt tccaaaagag aaacaccgga acatgttaca
6851 ataccagttt ccattttcat tatcttotct ggccaggata ttccatcc
6901 tctcccaagag caaaaagcga ctccacatag aagactactc tggttctcag
6951 acaacactt accaagtatt tgcactttt gccaaggacc aaagtgtatg
7001 tgaccactt aaagacctt cattacacaa aaaccagaca gtatggacg
7051 ttgcaggttt cacatctttt ctacaggatg agaaaatgtt gaaaagctat
7101 gtatggaaatcctgttcat acgggggtggc tgaaatgtt gagggacttag
7151 actttccatgtt gcaccatgtt aagtgttcat gagaatgtt ccagaatgtt
7201 atgtggaaatgtt aagtaatgtt gatactgtt gatacttattt caatgtcaatg
7251 caattcaatg

```

Figure 2: human ABC1 gene – protein translation

```

AAACCCCGTAATTGCGAGCGAGAGTGAGTGGGGCCGGGACCCGCAGAGCC
1 -----+-----+-----+-----+-----+ 50
GAGCCGACCCCTCTCTCCGGCTGCGGCAGGGCAGGGGGAGCTCCG
51 -----+-----+-----+-----+-----+ 100
CGCACCAACAGAGCCGGTCTCAGGGCGTTGCTCCTGTTTTCCCC
101 -----+-----+-----+-----+-----+ 150
GGTTCTGTTTCTCCCTTCTCCGAAGGCTTGTCAAGGGCTAGGAGAAA
151 -----+-----+-----+-----+-----+ 200
GAGACGCAAACACAAAAGTGGAAAACAGTTAATGACCAGCCACGGCGTCC
201 -----+-----+-----+-----+-----+ 250
CTGCTGTGAGCTCTGGCCGCTGCCCTCAGGGCTCCAGGCCACACGCTG
251 -----+-----+-----+-----+-----+ 300
GGGGTGCTGGCTGAGGGAACATGGCTTGTGGCCTCAGCTGAGGTTGCTG
301 -----+-----+-----+-----+-----+ 350
M A C W P Q L R L L -
CTGTGGAAGAACCTCACTTCAGAAGAAGAcaaaacatgtcagctgttact
351 -----+-----+-----+-----+-----+ 400
L W K N L T F R R R Q T C Q L L L -
ggaagtggcctggcctatattatcttgcctgtatctgttgcgc
401 -----+-----+-----+-----+-----+ 450
E V A W P L F I F L I L I S V R L -
tgagctaccaccatgaaacatgaatgcatttccaaataagcc
451 -----+-----+-----+-----+-----+ 500
S Y P P Y E Q H E C H F P N K A -
atgcctctgcaggaacacttcctgggttcaagggattatctgtatgc
501 -----+-----+-----+-----+-----+ 550
M P S A G T L P W V Q G I I C N A -
caacaaccctgtttccgttaccgactcctggggaggctccggagttg
551 -----+-----+-----+-----+-----+ 600
N N P C F R Y P T P G E A P G V V -

```

ttggaaactttaacaaatccattgtggctcgctgttcagatgctgg  
 601 -----+-----+-----+-----+-----+-----+ 650  
 G N F N K S I V A R L F S D A R -  
  
 aggcttctttatacagccagaaagacaccagcatgaaggacatgcgcaa  
 651 -----+-----+-----+-----+-----+-----+ 700  
 R L L L Y S Q K D T S M K D M R K -  
  
 agttctgagaacattacagcagatcaagaaatccagctcaaacttgaagc  
 701 -----+-----+-----+-----+-----+-----+ 750  
 V L R T L Q Q I K K S S S N L K L -  
  
 ttcaagatttctgggacaatgaaaccttctctgggtcctgtatcac  
 751 -----+-----+-----+-----+-----+-----+ 800  
 Q D F L V D N E T F S G F L Y H -  
  
 aacctctctcccaaagtctactgtggacaagatgctgagggctgtatgt  
 801 -----+-----+-----+-----+-----+-----+ 850  
 N L S L P K S T V D K M L R A D V - .  
  
  
 cattctccacaaggatattttgcaaggctaccagttacattgacaagtc  
 851 -----+-----+-----+-----+-----+-----+ 900  
 I L H K V F L Q G Y Q L H L T S L -  
  
 tggcaatggatcaaatacagaagagatgattcaacttgggtgaccaagaa  
 901 -----+-----+-----+-----+-----+-----+ 950  
 C N G S K S E E M I Q L G D Q E -  
  
 gtttctgagctttgtggctaccaagggagaaactggctgcagcagacg  
 951 -----+-----+-----+-----+-----+-----+ 1000  
 V S E L C G L P R E K L A A A E R -  
  
 agtacttcgttccaacatggacatcctgaagccaatcctgagaacactaa  
 1001 -----+-----+-----+-----+-----+-----+ 1050  
 V L R S N M D I L K P I L R T L N -  
  
 actctacatctcccttcccgagcaaggagctggccgaagccacaaaaaca  
 1051 -----+-----+-----+-----+-----+-----+ 1100  
 S T S P F P S K E L A E A T K T -  
  
 ttgctgcatagtctgggactctggcccaggagctttcagcatgagaag  
 1101 -----+-----+-----+-----+-----+-----+ 1150  
 L L H S L G T L A Q E L F S M R S -  
  
 ctggagtgacatgcgacaggagggtatgtttctgaccaatgtgaacagct  
 1151 -----+-----+-----+-----+-----+-----+ 1200  
 W S D M R Q E V M F L T N V N S S -  
  
 ccagctcccccacccaaatctaccaggctgtctcgattgtctgcggg  
 1201 -----+-----+-----+-----+-----+-----+ 1250  
 S S S T Q I Y Q A V S R I V C G -  
  
 catcccgagggagggggggctgaagatcaagtcacttcactggatgagga  
 1251 -----+-----+-----+-----+-----+-----+ 1300  
 H P E G G L K I K S L N W Y E D -  
  
 caacaactacaaaggccctttggaggcaatggactgaggaagatgctg  
 1301 -----+-----+-----+-----+-----+-----+ 1350  
 N N Y K A L F G G N G T E E D A E -  
  
 aaaccttctatgacaactctacaactcctactgcaatgatttgcata  
 1351 -----+-----+-----+-----+-----+-----+ 1400  
 T F Y D N S T T P Y C N D L M K -

aatttggagtctagtccctttccgcattatctggaaagctctgaagcc  
 1401 -----+-----+-----+-----+-----+-----+ 1450  
 N L E S S P L S R I I W K A L K P -  
  
 gctgctcggtggaaagatcctgtatacacctgacactccagccacaaggc  
 1451 -----+-----+-----+-----+-----+-----+ 1500  
 L L V G K I L Y T P D T P A T R Q -  
  
 aggtcatggctgaggtaacaagacccaggactggctgtgtccat  
 1501 -----+-----+-----+-----+-----+-----+ 1550  
 V M A E V N K T F Q E L A V F H -  
 gatctggaaaggcatgtggaggactcagcccaagatctggacccat  
 1551 -----+-----+-----+-----+-----+-----+ 1600  
 D L E G M W E E L S P K I W T F M -  
  
 ggagaacagccaagaatggacccgtccggatgctgtggacaggcagg  
 1601 -----+-----+-----+-----+-----+-----+ 1650  
 E N S Q E M D L V R M L L D S R D -  
  
 acaatgaccactttggaaacagcagttggatggcttagattggacagcc  
 1651 -----+-----+-----+-----+-----+-----+ 1700  
 N D H F W E Q Q L D G L D W T A -  
  
 caagacatcggtggcggtttggccaagcaccaggatgtccagtccag  
 1701 -----+-----+-----+-----+-----+-----+ 1750  
 Q D I V A F L A K H P E D V Q S S -  
  
 taatggttctgtgtacacctggagagaagctttcaacgagactaaccagg  
 1751 -----+-----+-----+-----+-----+-----+ 1800  
 N G S V Y T W R E A F N E T N Q A -  
  
 caatccggaccatatctcgcttcatggagtgtgtcaacctgaacaagcta  
 1801 -----+-----+-----+-----+-----+-----+ 1850  
 I R T I S R F M E C V N L N K L -  
  
 gaacccatagcaacagaagtctggctcatcaacaagtccatggagctgct  
 1851 -----+-----+-----+-----+-----+-----+ 1900  
 E P I A T E V W L I N K S M E L L -  
  
 ggtgagaggaagttctggctggattgtgttcaactggaaattactccag  
 1901 -----+-----+-----+-----+-----+-----+ 1950  
 D E R K F W A G I V F T G I T P G -  
  
 gcagcattgagctccccatcatgtcaagtacaagatccgaatggacatt  
 1951 -----+-----+-----+-----+-----+-----+ 2000  
 S I E L P H H V K Y K I R M D I -  
  
 gacaatgtggagaggacaaataaaatcaaggatgggtactgggaccctgg  
 2001 -----+-----+-----+-----+-----+-----+ 2050  
 D N V E R T N K I K D G Y W D P G -  
  
 tcctcgagctgaccctttgaggacatgcggtaacgtctggggggcttcg  
 2051 -----+-----+-----+-----+-----+-----+ 2100  
 P R A D P F E D M R Y V W G G F A -  
  
 cctacttgcaggatgtggtgaggcaatcatcagggtgctgacgggc  
 2101 -----+-----+-----+-----+-----+-----+ 2150  
 Y L Q D V V E Q A I I R V L T G -  
  
 accgagaagaaaactgggtctatatgcacacatgcctatccctgtta  
 2151 -----+-----+-----+-----+-----+-----+ 2200  
 T E K K T G V Y M Q Q M P Y P C Y -  
  
 cggtgatgacatcttctgcgggtatgagccggtaatgcctatccctgtta  
 2201 -----+-----+-----+-----+-----+-----+ 2250

## EP 1 136 552 A1

V D D I F L R V M S R S M P L F M -  
 tgacgctggcctggattactcagtggctgtatcatcaaggcatcg 2300  
 2251 -----+-----+-----+-----+-----+-----+  
 T L A W I Y S V A V I I K G I V -  
  
 tatgagaaggaggcacggctgaaagagaccatgcggatcatggcctg 2350  
 2301 -----+-----+-----+-----+-----+-----+  
 Y E K E A R L K E T M R I M G L D -  
  
 caacagcatcctctggtagctggttcattagtagcctcattccttc 2400  
 2351 -----+-----+-----+-----+-----+-----+  
 N S I L W F S W F I S S L I P L L -  
  
 ttgtgagcgtggcctgctagtggtcatcctgaagtttagaaacctgctg 2450  
 2401 -----+-----+-----+-----+-----+-----+  
 V S A G L L V V I L K L G N L L -  
  
 ccctacagtgtatcccagcgtgggtttgtcttctgtccgtgtttgctgt 2500  
 2451 -----+-----+-----+-----+-----+-----+  
 P Y S D P S V V F V F L S V F A V -  
  
 ggtgacaatcctgcagtgcattcattgatggacactcttcggagcca 2550  
 2501 -----+-----+-----+-----+-----+-----+  
 V T I L Q C F L I S T L F S R A N -  
  
 acctggcagcagcgtggggcatcatctacttacgctgtacctgccc 2600  
 2551 -----+-----+-----+-----+-----+-----+  
 L A A A C G G I I Y F T L Y L P -  
  
 tacgtcctgtgtggcatggcaggactacgtggcttcacactcaagat 2650  
 2601 -----+-----+-----+-----+-----+-----+  
 Y V L C V A W Q D Y V G F T L K I -  
  
 cttcgcttagcctgctgtcttggctttggctgtgact 2700  
 2651 -----+-----+-----+-----+-----+-----+  
 F A S L L S P V A F G F G C E Y F -  
  
 ttgccttttggaggcaggcattggagtgcaatggggacaacctgttt 2750  
 2701 -----+-----+-----+-----+-----+-----+  
 A L F E E Q G I G V Q W D N L F -  
  
 gagagtccgtggaggaagatggctcaatctaccacttcggctccat 2800  
 2751 -----+-----+-----+-----+-----+-----+  
 E S P V E D G F N L T T S V S M -  
  
 gatgctgttggacacccttcattgggtatgacctggatatttgg 2850  
 2801 -----+-----+-----+-----+-----+-----+  
 M L F D T F L Y G V M T W Y I E A -  
  
 ctgtcttccaggccagttacggaaatcccaggccctggatatttcctgc 2900  
 2851 -----+-----+-----+-----+-----+-----+  
 V F P G Q Y G I P R P W Y F P C -  
  
 accaagtccactgtttggcgaggaaagtgtatgagaagagccaccctgg 2950  
 2901 -----+-----+-----+-----+-----+-----+  
 T K S Y W F G E E S D E K S H P G -  
 ttccaaccagaagagaatatcagaaatctgcattggaggaggaaacccaccc 3000  
 2951 -----+-----+-----+-----+-----+-----+  
 S N Q K R I S E I C M E E E P T H -  
  
 acttgaagctggcggtccattcagaacctggtaaaagtctaccgagat 3050  
 3001 -----+-----+-----+-----+-----+-----+  
 L K L G V S I Q N L V K V Y R D -  
  
 gggatgaagggtggctgtcgatggcctggactgaattttatgagggcca 3100  
 3051 -----+-----+-----+-----+-----+-----+

EP 1 136 552 A1

G M K V A V D G L A L N F Y E G Q -  
 gatcacctccttcctggccacaatggagcgggaaagacgaccaccatgt  
 3101 -----+-----+-----+-----+-----+-----+ 3150  
 I T S F L G H N G A G K T T T M S -  
  
 caatcctgaccgggttgcgttccccgacctcgccaccgcctacatcctg  
 3151 -----+-----+-----+-----+-----+-----+ 3200  
 I L T G L F P P T S G T A Y I L -  
  
 ggaaaagacattcgctctgagatgagcaccatccggcagaacctgggg  
 3201 -----+-----+-----+-----+-----+-----+ 3250  
 G K D I R S E M S T I R Q N L G V -  
  
 ctgtcccccagcataacgtgctgtttgacatgctgactgtcgaagaacaca  
 3251 -----+-----+-----+-----+-----+-----+ 3300  
 C P Q H N V L F D M L T V E E H I -  
  
 tctggttctatgcccgttggaaagggtctctgagaagcacgtgaaggcg  
 3301 -----+-----+-----+-----+-----+-----+ 3350  
 W F Y A R L K G L S E K H V K A -  
  
 gagatggagcagatggccctggatgttggatggcatcaagcaagctgaa  
 3351 -----+-----+-----+-----+-----+-----+ 3400  
 E M E Q M A L D V G L P S S K L K -  
  
 aagcaaaacaagccagctgtcagggtggatgcagagaaagctatctgtgg  
 3401 -----+-----+-----+-----+-----+-----+ 3450  
 S K T S Q L S G G M Q R K L S V A -  
  
 cttggccttgcggggatctaagggtgtcattctggatgaacccaca  
 3451 -----+-----+-----+-----+-----+-----+ 3500  
 L A F V G G S K V V I L D E P T -  
  
 gctgggtggacccttactcccgcagggaaatatggagctgtcgtgaa  
 3501 -----+-----+-----+-----+-----+-----+ 3550  
 A G V D P Y S R R G I W E L L L K -  
  
 ataccgacaaggccgcaccattattctctcacacaccatggatgaag  
 3551 -----+-----+-----+-----+-----+-----+ 3600  
 Y R Q G R T I I L S T H H M D E A -  
  
 cggacgtcgtggggacaggattgccatcatctccatggaaagctgtgc  
 3601 -----+-----+-----+-----+-----+-----+ 3650  
 D V L G D R I A I I S H G K L C -  
 tgtgtgggtctccctgtttctgaaagaaccagctggaaacaggctacta  
 3651 -----+-----+-----+-----+-----+-----+ 3700  
 C V G S S L F L K N Q L G T G Y Y -  
  
 cctgaccttggtcaagaaagatgtggatcctccctcagttcctgcagaa  
 3701 -----+-----+-----+-----+-----+-----+ 3750  
 C L T L V K K D V E S S L S S C R N -  
  
 acagtagtagcactgtgtcataacctgaaaaaggaggacagtgtttctcag  
 3751 -----+-----+-----+-----+-----+-----+ 3800  
 S S S T V S Y L K K E D S V S Q -  
  
 agcagttctgtatgtggcctggcagcgaccatgagatgtgacacgctgac  
 3801 -----+-----+-----+-----+-----+-----+ 3850  
 S S S D A G L G S D H E S D T L T -  
  
 catcgatgtctgtctgtatctccaaacctcatcgaaagcatgtgtctgaaag  
 3851 -----+-----+-----+-----+-----+-----+ 3900  
 I D V S A I S N L I R K H V S E A -  
  
 cccggctggtggaaagacatagggcatgagctgacctatgtgctgccatat

EP 1 136 552 A1

3901 -----+-----+-----+-----+-----+ 3950  
     R L V E D I G H E L T Y V L P Y -  
  
     gaagctgctaaggaggagcttgtggactcttcatgagattgatga  
 3951 -----+-----+-----+-----+-----+ 4000  
     E A A K E G A F V E L F H E I D D -  
  
     ccggctctcagacctggcatttctagttatggcatctcagagacgaccc  
 4001 -----+-----+-----+-----+-----+ 4050  
     R L S D L G I S S Y G I S E T T L -  
  
     tggaagaaaatttcctcaaggtggccgaagagagtggggtggatgctgag  
 4051 -----+-----+-----+-----+-----+ 4100  
     E E I F L K V A E E S G V D A E -  
  
     acctcagatggtaccttgcacagcaagacgaaacaggcgcccttcgggaa  
 4101 -----+-----+-----+-----+-----+ 4150  
     T S D G T L P A R R N R R A F G D -  
  
     caagcagactgtctcgcccgtcactgaagatgatgctgatccaa  
 4151 -----+-----+-----+-----+-----+ 4200  
     K Q S C L R P F T E D D A A D P N -  
  
     atgattctgacatagaccagaatccagagagacagacttgcgtcagg  
 4201 -----+-----+-----+-----+-----+ 4250  
     D S D I D P E S R E T D L L S G -  
  
     atggatggcaaagggtcctaccaggtgaaaggctggaaacttacacagca  
 4251 -----+-----+-----+-----+-----+ 4300  
     M D G K G S Y Q V K G W K L T Q Q -  
  
     acagtttgccctttgtggaaagagactgctaattgccagacggagtc  
 4301 -----+-----+-----+-----+-----+ 4350  
     Q F V A L L W K R L L I A R R S R  
     ggaaaggatttttgcataatgttgcctgcagctgtgtttgtctgcatt  
 4351 -----+-----+-----+-----+-----+ 4400  
     K G F F A Q I V L P A V F V C I -  
  
     gcccttgcgttcagcctgatcgccacccttggcaagtacccagcct  
 4401 -----+-----+-----+-----+-----+ 4450  
     A L V F S L I V P P F G K Y P S L -  
  
     ggaacttcagccctggatgtacaacgaacagttcagcaatg  
 4451 -----+-----+-----+-----+-----+ 4500  
     E L Q P W M Y N E Q Y T F V S N D -  
  
     atgcctgaggacacggaaaccttggactcttaacgcctcaccaa  
 4501 -----+-----+-----+-----+-----+ 4550  
     A P E D T G T L E L L N A L T K -  
  
     gaccctggcttcgggaccgcgttatggaaaggaaacccaatcccagacac  
 4551 -----+-----+-----+-----+-----+ 4600  
     D P G F G T R C M E G N P I P D T -  
  
     gccctgccaggcaggggaggaagactggaccactgcccagttccccaga  
 4601 -----+-----+-----+-----+-----+ 4650  
     P C Q A G E E W T T A P V P Q T -  
  
     ccatcatggacctctccagaatggactggacaatgcagaacccatca  
 4651 -----+-----+-----+-----+-----+ 4700  
     I M D L F Q N G N W T M Q N P S -  
  
     cctgcattgcactgttagcagcggacaaaatcaagaagatgctgcctgtg  
 4701 -----+-----+-----+-----+-----+ 4750  
     P A C Q C S S D K I K K M L P V C -

EP 1 136 552 A1

tcccccaggggcagggggctgcctcctccacaaagaaaacaaaactg  
 4751 -----+-----+-----+-----+-----+-----+ 4800  
 P P G A G G L P P P Q R K Q N T A -  
  
 cagatataccttcaggacactgacaggaagaacattcgattatctggtg  
 4801 -----+-----+-----+-----+-----+-----+ 4850  
 D I L Q D L T G R N I S D Y L V -  
  
 aagacgtatgtgcagatcatagccaaaagcttaaaaagaaacatctgggt  
 4851 -----+-----+-----+-----+-----+-----+ 4900  
 K T Y V Q I I A K S L K N K I W V -  
  
 gaatgagtttaggtatggcggtttccctgggtgtcagtaatactcaag  
 4901 -----+-----+-----+-----+-----+-----+ 4950  
 N E F R Y G G F S L G V S N T Q A -  
  
 cacttcctccgagtcaagaagttaatgatgccaccaaaatgaagaaa  
 4951 -----+-----+-----+-----+-----+-----+ 5000  
 L P P S Q E V N D A T K Q M K K -  
  
 caccttaaagctggccaaggacagttctgcagatcgattctcaacagctt  
 5001 -----+-----+-----+-----+-----+-----+ 5050  
 H L K L A K D S S A D R F L N S L -  
 gggaaagatttatgacaggactggacaccagaataatgtcaagggtgtgg  
 5051 -----+-----+-----+-----+-----+-----+ 5100  
 G R F M T G L D T R N N V K V W F -  
  
 tcaataacaaggggctggcatgaatcagctttcctgaatgtcatcaac  
 5101 -----+-----+-----+-----+-----+-----+ 5150  
 N N K G W H A I S S F L N V I N -  
  
 aatgccatttcgcggccaacctgcaaaagggagagaaccctagccatta  
 5151 -----+-----+-----+-----+-----+-----+ 5200  
 N A I L R A N L Q K G E N P S H Y -  
  
 tggaattactgcttcaatcatcccctgaatctcaccaagcagcagctct  
 5201 -----+-----+-----+-----+-----+-----+ 5250  
 G I T A F N H P L N L T K Q Q L S -  
  
 cagagggtggctccgatgaccacatcagtggatgtcctgtgtccatctgt  
 5251 -----+-----+-----+-----+-----+-----+ 5300  
 E V A P M T T S V D V L V S I C -  
  
 gtcatcttgcaatgtcattgtccagccagcttgcgtattcctgat  
 5301 -----+-----+-----+-----+-----+-----+ 5350  
 V I F A M S F V P A S F V V F L I -  
  
 ccaggagcgggtcagcaaagcaaacacacctgcagttcatcagtggagtga  
 5351 -----+-----+-----+-----+-----+-----+ 5400  
 Q E R V S K A K H L Q F I S G V K -  
  
 agcctgtcatctactggctcttaatttgtctggatatgtcaattac  
 5401 -----+-----+-----+-----+-----+-----+ 5450  
 P V I Y W L S N F V W D M C N Y -  
  
 gttgtccctgccacactggtcattatcatctgcatttcagcagcagaa  
 5451 -----+-----+-----+-----+-----+-----+ 5500  
 V V P A T L V I I I F I C F Q Q K -  
  
 gtcctatgtgtcctccaccaatctgcctgtgcatttcgcattttgc  
 5501 -----+-----+-----+-----+-----+-----+ 5550  
 S Y V S S T N L P V L A L L L L -  
  
 tgtatgggtggtcaatcacacctctcatgtacccagcctccttgc  
 5551 -----+-----+-----+-----+-----+-----+ 5600  
 Y G W S I T P L M Y P A S F V F -

aagatccccagcacagcctatgtggtgctaccagcgtgaacctcttc  
 5601 -----+-----+-----+-----+-----+-----+ 5650  
 K I P S T A Y V V L T S V N L F I -  
  
 tggcattaatggcagcgtggccaccccttgcgtggagcttgcaccgaca  
 5651 -----+-----+-----+-----+-----+-----+ 5700  
 G I N G S V A T F V L E L F T D N -  
  
 ataagctgaataatcaatgatatacctgaagtccgttgcattatc  
 5701 -----+-----+-----+-----+-----+-----+ 5750  
 K L N N I N D I L K S V F L I F -  
 ccacattttgcctggacgaggcgtcatgcacatggtaaaaaaccaggc  
 5751 -----+-----+-----+-----+-----+-----+ 5800  
 P H F C L G R G L I D M V K N Q A -  
  
 aatggctgatgccctggaaagggttggggagaatcgcttgcaccat  
 5801 -----+-----+-----+-----+-----+-----+ 5850  
 M A D A L E R F G E N R F V S P L -  
  
 tatcttggacttgggtggacgaaaccttcgcctatggccgtggaaagg  
 5851 -----+-----+-----+-----+-----+-----+ 5900  
 S W D L V G R N L F A M A V E G -  
  
 gtgggttttcctcattactgttctgatccagtttc  
 5901 -----+-----+-----+-----+-----+-----+ 5950  
 V V F F L I T V L I Q Y R F F I R -  
  
 gcccagacctgtaaatgcaaagctatccctctgaatgatgaagatgaag  
 5951 -----+-----+-----+-----+-----+-----+ 6000  
 P R P V N A K L S P L N D E D E D -  
  
 atgtgaggcgggaaagacagagaattcttgcgtggaggccagaatgac  
 6001 -----+-----+-----+-----+-----+-----+ 6050  
 V R R E R Q R I L D G G G Q N D -  
  
 atcttagaaatcaaggagttgacgaagatataagaaggaaagcggaaagcc  
 6051 -----+-----+-----+-----+-----+-----+ 6100  
 I L E I K E L T K I Y R R K R K P -  
  
 tgctgttgcacaggattgcgtgggcattccctcgttgagtgcttgggc  
 6101 -----+-----+-----+-----+-----+-----+ 6150  
 A V D R I C V G I P P G E C F G L -  
  
 tcctggaggttaatggggctggaaatcatcaacttcaagatgttaaca  
 6151 -----+-----+-----+-----+-----+-----+ 6200  
 L G V N G A G K S S T F K M L T -  
  
 ggagataccactgttaccagaggagatgtttcctaacagaaatagtt  
 6201 -----+-----+-----+-----+-----+-----+ 6250  
 G D T T V T R G D A F L N R N S I -  
  
 cttatcaaacatccatgaagtacatcagaacatggctactgcctcagt  
 6251 -----+-----+-----+-----+-----+-----+ 6300  
 L S N I H E V H Q N M G Y C P Q F -  
  
 ttgatgccatcacagagctgttgcgtggagagaacacgtggagtttt  
 6301 -----+-----+-----+-----+-----+-----+ 6350  
 D A I T E L L T G R E H V E F F -  
  
 gcccctttgagaggagtcctccagagaaggaaaggatggcaaggttgg  
 6351 -----+-----+-----+-----+-----+-----+ 6400  
 A L L R G V P E K E V G K V G E W -  
  
 ggcgattcgaaaactggccctcgtaagtatggagaaaaatatgtggta  
 6401 -----+-----+-----+-----+-----+-----+ 6450

## EP 1 136 552 A1

A I R K L G L V K Y G E K Y A G N -  
 actata tagtggaggcaacaaacgc aacgc aacgc tctacagccatggcttgate  
 6451 -----+-----+-----+-----+-----+ 6500  
 Y S G G N K R K L S T A M A L I -  
  
 ggcgggcctcctgtgggtttctggatgaacccaccacaggcatggatcc  
 6501 -----+-----+-----+-----+-----+ 6550  
 G G P P V V F L D E P T T G M D P -  
  
 caaagcccccgggttctgtggattgtgcctaagtgttcaaggagg  
 6551 -----+-----+-----+-----+-----+ 6600  
 K A R R F L W N C A L S V V K E G -  
  
 ggagatcagtagtgc ttacatctcatagtagtggagaatgtgaagcttt  
 6601 -----+-----+-----+-----+-----+ 6650  
 R S V V L T S H S M E E C E A L -  
  
 tgcactaggatggcaatcatggtaatggaaaggttcagggtgc ttggcag  
 6651 -----+-----+-----+-----+-----+ 6700  
 C T R M A I M V N G R F R C L G S -  
  
 tgtccagcatctaaaaatagggttggagatggttataacaataggtagtac  
 6701 -----+-----+-----+-----+-----+ 6750  
 V Q H L K N R F G D G Y T I V V R -  
  
 gaatagcagggtccaacccggacctgaaggctgtccaggatttcttgg  
 6751 -----+-----+-----+-----+-----+ 6800  
 I A G S N P D L K P V Q D F F G -  
  
 cttgcatttccttggaaagtgttccaaaagagaaaacaccggAACatgtaca  
 6801 -----+-----+-----+-----+-----+ 6850  
 L A F P G S V P K E K H R N M L Q -  
  
 ataccagcttccatttcattatcttctgtggccaggatattcagcatcc  
 6851 -----+-----+-----+-----+-----+ 6900  
 Y Q L P S S L S S L A R I F S I L -  
  
 tctcccagagaaaaagcgaactccacatagaagactactstgtttcttag  
 6901 -----+-----+-----+-----+-----+ 6950  
 S Q S K K R L H I E D Y S V S Q -  
  
 acaacacttgaccaagtattgtgaactttgccaaggaccaaggatgtga  
 6951 -----+-----+-----+-----+-----+ 7000  
 T T L D Q V F V N F A K D Q S D D -  
  
 tgaccacttaaaagacctctcattacacaaaaaccagacagactgtggacg  
 7001 -----+-----+-----+-----+-----+ 7050  
 D H L K D L S L H K N Q T V V D V -  
  
 ttgcagttctcacattttctacaggatgagaaaagtggaaaggactat  
 7051 -----+-----+-----+-----+-----+ 7100  
 A V L T S F L Q D E K V K E S Y -  
  
 gtatgaagaatcctgttcatacgggggtggctgaaaatggggactag  
 7101 -----+-----+-----+-----+-----+ 7150  
 V \*  
  
 actttccttgcaccaatgtgaagtgttggagaaaagagccagaatgg  
 7151 -----+-----+-----+-----+-----+ 7200  
  
 atgtgggaagaagtaaactggatactgtactgatactattcaatgcatt  
 7201 -----+-----+-----+-----+-----+ 7250  
  
 caattcaatg

**EP 1 136 552 A1**

7251 -----+ 7260



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
D, X	BODZIOCH M ET AL: "THE GENE ENCODING ATP-BINDING CASSETTE TRANSPORTER 1 IS MUTATED IN TANGIER DISEASE" NATURE GENETICS, NEW YORK, NY, US, vol. 22, no. 4, August 1999 (1999-08), pages 347-351, XP000889766 ISSN: 1061-4036 * page 349, column 2, line 3 * -----	1-11, 14, 15	C12N15/12 C12N15/11 C12N9/00 C12N5/10 C07K14/705 C07K16/28 C1201/68 G01N33/53 A61K48/00
D, X	BROOKS-WILSON A ET AL: "MUTATIONS IN ABC1 IN TANGIER DISEASE AND FAMILIAL HIGH-DENSITY LIPOPROTEIN DEFICIENCY" NATURE GENETICS, NEW YORK, NY, US, vol. 22, no. 4, August 1999 (1999-08), pages 336-345, XP000889767 ISSN: 1061-4036 * figures 7, 8 * ----- -----	8-10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12N C07K C12Q G01N A61K
INCOMPLETE SEARCH			
The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.			
Claims searched completely			
Claims searched incompletely			
Claims not searched			
Reason for the limitation of the search			
see sheet C			
Place of search	Date of completion of the search	Examiner	
THE HAGUE	5 December 2000	Lonnoy, O	
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			
T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

European Patent  
OfficeINCOMPLETE SEARCH  
SHEET C

Application Number

EP 00 10 5820

Claim(s) not searched:  
12,13

## Reason for the limitation of the search:

Present claims 12 and 13 relate to a compound defined by reference to a desirable characteristic or property, namely that it is a modulator of polypeptides of the invention. The claims cover all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for no such compound. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, no search can be carried out for such claims, the wording of which is a mere recitation of the results to be achieved.



Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
D, X	LAWN R M ET AL: "THE TANGIER DISEASE GENE PRODUCT ABC1 CONTROLS THE CELLULAR APOLIPOPROTEIN-MEDIATED LIPID REMOVAL PATHWAY" JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 104, no. 8, October 1999 (1999-10), pages R25-R31, XP000884782 ISSN: 0021-9738 * figures 2-5 *	8-10	
E	WO 00 18912 A (BAYER AG ;KLUCKEN JOCHEN (DE); SCHMITZ GERD (DE)) 6 April 2000 (2000-04-06) SeqIdNo.1: 100.0% identity in 6880 bp overlap with SeqIdNo.1 / SeqIdNo.2: 100.0% identity in 2201 aa overlap with SeqIdNo.2	8-10	
A	YOUNG S G ET AL: "THE ABCS OF CHOLESTEROL EFFLUX" NATURE GENETICS, US, NEW YORK, NY, vol. 22, no. 4, August 1999 (1999-08), pages 316-318, XP000889764 ISSN: 1061-4036	-----	

**CLAIMS INCURRING FEES**

The present European patent application comprised at the time of filing more than ten claims.

Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):

No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

**LACK OF UNITY OF INVENTION**

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.

As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.

Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:

None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-15 (all partially)

G596A allele of ABC1, recombinant methods, products, therapeutic, and diagnostic applications relating thereto.

2. Claims: 1-15 (all partially)

T1136C allele of ABC1, recombinant methods, products, therapeutic, and diagnostic applications relating thereto.

3. Claims: 1-15 (all partially)

A2589G allele of ABC1, recombinant methods, products, therapeutic, and diagnostic applications relating thereto.

4. Claims: 1-15 (all partially)

G3456C allele of ABC1, recombinant methods, products, therapeutic, and diagnostic applications relating thereto.

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 10 5820

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

05-12-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0018912 A	06-04-2000	AU 5980499 A	17-04-2000